

## PCT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 18 May 1999 (18.05.99)	
<b>International application No.</b> PCT/US98/19028	<b>Applicant's or agent's file reference</b> 15280-3682PC
<b>International filing date</b> (day/month/year) 11 September 1998 (11.09.98)	<b>Priority date</b> (day/month/year) 11 September 1997 (11.09.97)
<b>Applicant</b> BERZOFSKY, Jay, A. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
09 April 1999 (09.04.99)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer R. E. Stoffel</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---



# TENT COOPERATION TREA

LKP

From the INTERNATIONAL SEARCHING AUTHORITY

## PCT

To: 59 APR -9 9:43  
**TOWNSEND AND TOWNSEND AND CREW LLP**  
 Attn. KING, J.  
 Two Embarcadero Center, 8th Floor  
 San Francisco, CA 94111-3834  
 UNITED STATES OF AMERICA

RECEIVED

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

Applicant's or agent's file reference <b>15280-3682PC</b>	Date of mailing (day/month/year) <b>29/03/1999</b>
International application No. <b>PCT/US 98/19028</b>	International filing date (day/month/year) <b>11/09/1998</b>
Applicant <b>THE GOVERNEMNT OF THE UNITED STATES ..... et al.</b>	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:** 5/29/99  
 The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland  
 Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following: 3/11/99

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later) 4/11/99

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II. 3/11/00 5/11/99

Name and mailing address of the International Searching Authority European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <b>Barbara Klaver</b> <span style="float: right; font-family: cursive;">AKK</span>
--	--



## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.



## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.





# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>15280-3682PC</b> ✓	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 98/ 19028</b> ✓	International filing date (day/month/year) <b>11/09/1998</b> ✓	(Earliest) Priority Date (day/month/year) <b>11/09/1997</b> ✓
Applicant  <b>THE GOVERNMENT OF THE UNITED STATES ..... et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/19028

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-45 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/19028

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K39/00 A61K39/39 A61K38/19 A61K39/21 A61K39/145  
 A61K39/15 A61K39/02 A61K39/002 A61K9/00 //(A61K39/21,  
 38:20), (A61K39/21, 39:106, 38:20)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PORGADOR E.A.: "Intranasal immunisation with CTL epitope peptide from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo" JOURNAL OF IMMUNOLOGY, vol. 158, no. 2, 15 January 1997, pages 834-841, XP002096388 BALTIMORE US	1-20, 25-41, 46-69
Y	see the whole document --- -/--	21-24, 42-45

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

12 March 1999

Date of mailing of the international search report

29/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/19028

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PARTIDOS E.A.: "The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of E.coli for the induction of measles virus-specific CTL responses after intranasal co-immunisation with a synthetic peptide" IMMUNOLOGY, vol. 89, 1996, pages 483-487, XP002096389	1-20, 25-41, 46-69
Y	see the whole document	21-24, 42-45
X	--- KLAVINSKIS E.A.: "Mucosal or targeted lymph node immunisation of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes" JOURNAL OF IMMUNOLOGICAL METHODS, vol. 157, no. 6, 15 September 1996, pages 2521-2527, XP002096390 NEW YORK US	1-20, 25-41, 46-69
Y	cited in the application see the whole document	21-24, 42-45
X	--- PARTIDOS E.A.: "Mucosal immunization with a measles virus CTL epitope encapsulated in biodegradable PLG microparticles" JOURNAL OF IMMUNOLOGICAL METHODS, vol. 195, 1996, pages 135-138, XP002096391	1-20, 25-41, 46-69
Y	see the whole document	21-24, 42-45
Y	--- WO 94 26785 A (US HEALTH) 24 November 1994 cited in the application see the whole document	<del>21-24,</del> <del>42-45</del>
P,X	--- BELYAKOV E.A.: "Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic CTL's and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 95, no. 4, 17 February 1998, pages 1709-1714, XP002096392 WASHINGTON US cited in the application see the whole document --- -/--	1-69





## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/19028

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AHLERS E.A.: "Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs" JOURNAL OF IMMUNOLOGICAL METHODS, vol. 158, no. 8, 15 April 1997, pages 3947-3958, XP002096393 NEW YORK US cited in the application see the whole document -----	
A	GALLICHAN E.A.: "Long-lived CTL memory in mucosal tissue after mucosal but not systemic immunization" J.EXP.MED., vol. 184, November 1996, pages 1879-1890, XP002096394 cited in the application see the whole document -----	
A	LANGERMANN: "New approaches to mucosal immunization" SEMINARS IN GASTROINTESTINAL DISEASE, no. 7, 1901 - January 1996, pages 12-18, XP002096395 see abstract -----	



## INTERNATIONAL SEARCH REPORT

on patent family members

International Application No

PCT/US 98/19028

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426785 A	24-11-1994	AU 688333 B	12-03-1998
		AU 7017394 A	12-12-1994
		EP 0701572 A	20-03-1996
		JP 9500614 T	21-01-1997
-----			



# PATENT COOPERATION TREATY

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:   
KING, Jeffrey J. et al.  
TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
ETATS-UNIS D'AMERIQUE

22 JUL -6 AM 11:04  
RECEIVED

PCT

WRITTEN OPINION

(PCT Rule 66)

Date of mailing (day/month/year) <b>29.06.99</b>	
Applicant's or agent's file reference <b>15280-3682PC</b>	<b>REPLY DUE</b> within 3 month(s) <b>9-29-99</b> from the above date of mailing
International application No. <b>PCT/US98/19028</b>	International filing date (day/month/year) <b>11/09/1998</b>
Priority date (day/month/year) <b>11/09/1997</b>	
International Patent Classification (IPC) or both national classification and IPC <b>A61K39/00</b>	
Applicant <b>THE GOVERNMENT OF THE UNITED STATES ..... et al.</b>	

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
  - I ☒ Basis of the opinion
  - II ☐ Priority
  - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV ☐ Lack of unity of invention
  - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI ☐ Certain document cited
  - VII ☒ Certain defects in the international application
  - VIII ☒ Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.


**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

**If no reply is filed**, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **11/01/2000**.

Name and mailing address of the international preliminary examining authority:  
 European Patent Office  
D-80298 Munich  
Tel. (+49-89) 2399-0 Tx: 523656 epmu d  
Fax: (+49-89) 2399-4465

Authorized officer / Examiner

von Ballmoos, P

Formalities officer (incl. extension of time limits)

Danti, B

Telephone No. (+49-89) 2399 8161



**DOCKETED** 



**I. Basis of the opinion**

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

**Description, pages:**

1-59 as originally filed

**Claims, No.:**

1-69 as originally filed

**Drawings, sheets:**

1/17-17/17 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims	1-4, 15-16, 20, 25, 36-37, 41, 46, 59-60, 65-66 (No)
Inventive step (IS)	Claims	5-14, 17-19, 21-24, 26-35, 38-40, 42-45, 47-58, 61-64, 67-69 (No)
Industrial applicability (IA)	Claims	1-45 (?)

**2. Citations and explanations**

**s s parat sheet**





**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**



Reference is made to the following documents:

- D1 Journal of Immunology, 158(2), 1997, 834-841
- D2 Immunology, 89, 1996, 483-487
- D3 Journal of Immunological Methods, 157(6), 1996, 2521-2527
- D4 Journal of Immunological Methods, 195, 1996, 135-138
- D5 WO-A-94 26785
- D6 PNAS, 95(4), 1998, 1709-1714
- D7 Journal of Immunological Methods, 158(8), 1997, 3947-3958

## **Part I**

The pages of the sequence listings (which form part of the description as they have been originally filed) have not been numbered consecutively to the description pages as requested by R. 11.7 PCT.

## **Part V**

### **a) Prior art and Novelty**

**D1** discloses a method of mucosal immunization to induce specific CTL response with a composition comprising the mucosal adjuvant cholera toxin (CT) and CTL epitope peptides. It appears to be inherent that this method induces **mucosal** CTL response. Apparently, the corresponding experiments merely had not yet been performed although they were suggested (see last paragraph). The methods of the present application therefore do not appear to contain a new teaching. Useful epitopes are e.g. R10I corresponding to amino acids 318-327 from the V3 loop of HIV-1-IIIB gp120 and R15K corresponding to amino acids 315-329 of HIV-1-IIIB gp 120 and the tumor associated OVA-peptide (see abstract and chapter "Peptides"). Experiments without addition of adjuvants were also performed (see chapter "Immunizations").

From the above, it is apparent that D1 discloses all the technical features of independent claims 1, 25 and 46. It is therefore prejudicial to the novelty of these claims as well as to the novelty of claims 2-4, 15-16, 20, 36-37, 41, 59-60, 65-66 (Art.



33(2) PCT).

**D2** discloses a composition comprising a measles virus CTL epitope and LTK63 as adjuvant. LTK63 is a non-toxic mutant of heat labile enterotoxin of *E. coli* having a single substitution of Ser-63 to Lys in the A subunit. The composition is intranasally administered to mice to induce measles virus specific CTL responses. It appears to be an inherent feature of this method that **mucosal** response is induced.

Comparative experiments with compositions containing the non-mutated LT toxin or no adjuvant at all (see Figures 1-2 and chapter "Immunization") are also performed.

D2 therefore discloses all the technical features of claims 1-4, 15, 25, 36, 46, 59-60 and takes away their novelty (Art. 33(2) PCT).

**D3** provides evidence that mucosal immunization with an SIV protein can generate anti-SIV CTL in the rectal and genital mucosa, in the draining LNs and in the central lymphoid system (see abstract and "Results, Mucosal Immunization"). The composition used for the mucosal immunization comprises recombinant SIVp27 gag fused to Ty virus-like particles (Ty-VLP) as an Ag carrier; SIVp27:Ty-VLP is covalently linked to the adjuvant cholera toxin B subunit (see introduction and "Immunization schedule").

Hence, it appears that D3 takes away the novelty of claims 1-4, 15, 46, 59-60 (Art. 33(2) PCT).

**D4** discloses measles virus (MV) specific CTL responses after intranasal immunization of mice with a composition containing the NP6 CTL epitope from MV nucleoprotein. Compositions with CTB adjuvant as well as adjuvant free compositions are tested and both give better CTL responses than NP6 epitopes encapsulated in microparticles.

Hence, D4 is prejudicial to the novelty of claims 1-4, 15, 25, 46, 59-60 (Art. 33(2) PCT).

**D5** discloses HIV peptides which comprise covalently linked Th epitopes, CTL epitopes and epitopes which elicit a neutralizing antibody response. These antigens are used in connection with a saponin adjuvant to immunize mice subcutaneously or



intraperitoneally in order to elicit CTL against HIV-1 (see examples 2 and 3).

The antigens are identical to the antigens of the present application with the SEQ ID numbers 1-14 (for SEQ ID NO: 1-SEQ ID NO:7 see Table 1, page 14; for SEQ ID NO: 8-SEQ ID NO:14 see Table VI, page 51).

Vaccination of humans with these constructs is suggested (see Example V).

**D7** discloses subcutaneous immunization of mice with a composition containing the antigens SEQ: 9 and SEQ: 12 of the present invention, an adjuvant and cytokines (see "Antigens" and "Cytokines and Immunization"). It is emphasised that the cytokines should be directly delivered to the microenvironment in which the immune response is initiated. The cytokines used are IL-2, IL-4, IL-7, IL-1 $\beta$ , IL-12, IFN- $\gamma$ , TNF- $\gamma$  and GM-CSF (abstract).

#### **b) Inventive step**

Dependent claims 5-14, 17-19, 21-24, 26-35, 38-40, 42-45, 47-58, 61-64 and 67-69 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step (Art. 33(3) PCT), the reasons being as follows:

- The skilled person knows from D7 that cytokines can enhance an immune response when they are directly delivered to the microenvironment in which the immune response is initiated. In order to improve the CTL response in mucosal immunization, he would therefore administer the cytokines to the mucosa surface without exercise of inventive skill. Hence, claims 5-14, 26-35, 67-69 do not meet the requirements of Art. 33(3) PCT.
- The use of selected CLUVAC HIV peptides according to claims 21-24 and 42-45 does not appear to be inventive as the skilled person knows from D5 and D7 that these sequences are particularly suitable to induce a CTL response. He would therefore apply them also with an expectation of success for the induction of mucosal CTL.
- The additional features of claims 17-19, 38-40, 47-58, 61-64 are merely





conventional as they relate to the use of the method for different antigens, to the addition of known agents for the improvement of rectal antigen administration and to modified adjuvants. These additional features do not result in an unexpected effect and would have been applied by the skilled person in his routine work.

**c) Industrial Applicability**

For the assessment of the present claims 1-45 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**d) Document D6**

This document discloses mucosal immunization with HIV-1 peptide vaccines. Mucosal and systemic cytotoxic T lymphocytes are induced as well as protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Cholera toxin adjuvant, while enhancing the response, was not essential. The peptides used are identical to those of the present application.

This document therefore, would appear to disclose or make obvious the subject-matter of claims 1-69.

However, the current assessment is based on the assumption that all claims enjoy priority rights from the priority document. The present priority date of 11.09.1997 is, namely, before the publication date of D6 (17.02.1998). If it later turns out that the assumption is not correct, document D6 could become relevant.

**Part VII**

- a) Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art



disclosed in the documents D1, D2, D4 is not mentioned in the description, nor are these documents identified therein.

- b) The expression "herein incorporated by reference" or equivalents thereof (see pages 14 and 15) will have to be deleted in some cases when entering the national or regional phase (see e.g. the Guidelines for Examination in the EPO, C-II, 4.18). The reference to non-published patent applications will also have to be changed to published publication numbers throughout the application.
- c) Dependent claims 6 and 27 should be changed to read "...a cytokine" instead of "...the cytokine" as the independent claims do not mention a cytokine.
- d) The statement on page 1, first paragraph has no bearing on the invention or its background art and should thus be deleted as being irrelevant (Art. 6, Rule 9.1 (iv) PCT).

#### **Part VIII**

- a) The groups of claims 8, 9, 10, 11 and 31, 32 respectively appear to have identical scope. This redundancy renders the set of claims unclear (Art. 6 PCT). Therefore, it appears appropriate to delete claims 9, 10, 11 and 32.
- b) It is apparent from the description (see e.g. page 50) that IL-12 is only useful for improving protective mucosal CTL response in a mammal when it is mucosally administered. Claim 7 which encompasses systemic application of IL-12 is contradictory to this teaching and therefore does not meet the requirements of Art. 6 PCT.
- c) The vague and imprecise statement ("spirit of invention") in the description on page 52 implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, PCT/GL/3 III, 4.3a).



# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

**ACG**

~~KING, Jeffrey J. et al.~~

TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
ETATS-UNIS D'AMERIQUE

TOWNSEND & TOWNSEND  
& CREW

99 OCT 22 AM 8:24  
**PCT**

RECEIVED

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT  
(PCT Rule 71.1)

Date of mailing  
(day/month/year)

**21. 10. 99**

Applicant's or agent's file reference  
15280-3682PC

## IMPORTANT NOTIFICATION

International application No.  
PCT/US98/19028      /

International filing date (day/month/year)  
11/09/1998      /

Priority date (day/month/year)  
11/09/1997      /

Applicant

THE GOVERNMENT OF THE UNITED STATES ..... et al.      /

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

### 4. REMINDER

3-11-00 a.

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Digiusto, M

Tel. +49 89 2399-8162





# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>15280-3682PC</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/US98/19028</b>	International filing date ( <i>day/month/year</i> ) <b>11/09/1998</b>	Priority date ( <i>day/month/year</i> ) <b>11/09/1997</b>
International Patent Classification (IPC) or national classification and IPC <b>A61K39/00</b>		
Applicant <b>THE GOVERNEMNT OF THE UNITED STATES ..... et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 10 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I    ☒ Basis of the report
- II   ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV   ☐ Lack of unity of invention
- V    ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI   ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>09/04/1999</b>	Date of completion of this report  <div style="text-align: right; font-size: 1.2em;"><b>21. 10. 99</b></div>
Name and mailing address of the international preliminary examining authority:  <div style="display: flex; align-items: center;"> <div>             European Patent Office              D-80298 Munich              Tel. +49 89 2399 - 0 Tx: 523656 epmu d              Fax: +49 89 2399 - 4465           </div> </div>	Authorized officer  <b>von Ballmoos, P</b>  Telephone No. +49 89 2399 8174







**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/19028

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-59 as originally filed

**Claims, No.:**

1-69 as originally filed

**Drawings, sheets:**

1/17-17/17 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.  
☒ claims Nos. 1-45 with respect to industrial applicability.

because:



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/19028

- ☒ the said international application, or the said claims Nos. 1-45 relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

- ☐ no international search report has been established for the said claims Nos. .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	5-14, 17-19, 21-24, 26-35, 38-40, 42-45, 47-58, 61-64, 67-69
	No:	Claims	1-4, 15-16, 20, 25, 36-37, 41, 46, 59-60, 65-66
Inventive step (IS)	Yes:	Claims	---
	No:	Claims	1-69
Industrial applicability (IA)	Yes:	Claims	46-69
	No:	Claims	---

**2. Citations and explanations**

**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:

**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/19028

---

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**



**Part I**

The pages of the sequence listings are considered to form part of the description as they have been originally filed.

**Part III**

Claims 1-45 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Part V**

Reference is made to the following documents:

- D1 Journal of Immunology, 158(2), 1997, 834-841
- D2 Immunology, 89, 1996, 483-487
- D3 Journal of Immunological Methods, 157(6), 1996, 2521-2527
- D4 Journal of Immunological Methods, 195, 1996, 135-138
- D5 WO-A-94 26785
- D6 PNAS, 95(4), 1998, 1709-1714
- D7 Journal of Immunological Methods, 158(8), 1997, 3947-3958

**a) Prior art and Novelty**

**D1** discloses a method of mucosal immunization to induce specific CTL response with a composition comprising the mucosal adjuvant cholera toxin (CT) and CTL epitope peptides. It appears to be inherent that this method induces **mucosal** CTL response. Apparently, the corresponding experiments merely had not yet been performed although they were suggested (see last paragraph). The methods of the present application therefore do not appear to contain a new teaching.





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/19028

Useful epitopes are e.g. R10I corresponding to amino acids 318-327 from the V3 loop of HIV-1-IIIB gp120 and R15K corresponding to amino acids 315-329 of HIV-1-IIIB gp120 and the tumor associated OVA-peptide (see abstract and chapter "Peptides"). Experiments without addition of adjuvants were also performed (see chapter "Immunizations").

From the above, it is apparent that D1 discloses all the technical features of independent claims 1, 25 and 46. It is therefore prejudicial to the novelty of these claims as well as to the novelty of claims 2-4, 15-16, 20, 36-37, 41, 59-60, 65-66 (Art. 33(2) PCT).

**D2** discloses a composition comprising a measles virus CTL epitope and LTK63 as adjuvant. LTK63 is a non-toxic mutant of heat labile enterotoxin of E. coli having a single substitution of Ser-63 to Lys in the A subunit. The composition is intranasally administered to mice to induce measles virus specific CTL responses. It appears to be an inherent feature of this method that **mucosal** response is induced. Comparative experiments with compositions containing the non-mutated LT toxin or no adjuvant at all (see Figures 1-2 and chapter "Immunization") are also performed.

D2 therefore discloses all the technical features of claims 1-4, 15, 25, 36, 46, 59-60 and takes away their novelty (Art. 33(2) PCT).

**D3** provides evidence that mucosal immunization with an SIV protein can generate anti-SIV CTL in the rectal and genital mucosa, in the draining LNs and in the central lymphoid system (see abstract and "Results, Mucosal Immunization"). The composition used for the mucosal immunization comprises recombinant SIVp27 gag fused to Ty virus-like particles (Ty-VLP) as an Ag carrier; SIVp27:Ty-VLP is covalently linked to the adjuvant cholera toxin B subunit (see introduction and "Immunization schedule").

Hence, it appears that D3 takes away the novelty of claims 1-4, 15, 46, 59-60 (Art. 33(2) PCT).

**D4** discloses measles virus (MV) specific CTL responses after intranasal immunization of mice with a composition containing the NP6 CTL epitope from MV nucleoprotein. Compositions with CTB adjuvant as well as adjuvant free compositions are tested and



both give better CTL responses than NP6 epitopes encapsulated in microparticles.

Hence, D4 is prejudicial to the novelty of claims 1-4, 15, 25, 46, 59-60 (Art. 33(2) PCT).

**D5** discloses HIV peptides which comprise covalently linked Th epitopes, CTL epitopes and epitopes which elicit a neutralizing antibody response. These antigens are used in connection with a saponin adjuvant to immunize mice subcutaneously or intraperitoneally in order to elicit CTL against HIV-1 (see examples 2 and 3).

The antigens are identical to the antigens of the present application with the SEQ ID numbers 1-14 (for SEQ ID NO: 1-SEQ ID NO:7 see Table 1, page 14; for SEQ ID NO: 8-SEQ ID NO:14 see Table VI, page 51).

Vaccination of humans with these constructs is suggested (see Example V).

**D7** discloses subcutaneous immunization of mice with a composition containing the antigens SEQ: 9 and SEQ: 12 of the present invention, an adjuvant and cytokines (see "Antigens" and "Cytokines and Immunization"). It is emphasised that the cytokines should be directly delivered to the microenvironment in which the immune response is initiated. The cytokines used are IL-2, IL-4, IL-7, IL-1[SPEC0803], IL-12, IFN-[SPEC0807], TNF-[SPEC0807] and GM-CSF (abstract).

#### **b) Inventive step**

Dependent claims 5-14, 17-19, 21-24, 26-35, 38-40, 42-45, 47-58, 61-64 and 67-69 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step (Art. 33(3) PCT), the reasons being as follows:

- The skilled person knows from D7 that cytokines can enhance an immune response when they are directly delivered to the microenvironment in which the immune response is initiated. In order to improve the CTL response in mucosal immunization, he would therefore administer the cytokines to the mucosa surface without exercise of inventive skill. Hence, claims 5-14, 26-35, 67-69 do not meet the requirements of Art. 33(3) PCT.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/19028

- The use of selected CLUVAC HIV peptides according to claims 21-24 and 42-45 does not appear to be inventive as the skilled person knows from D5 and D7 that these sequences are particularly suitable to induce a CTL response. He would therefore apply them also with an expectation of success for the induction of mucosal CTL.
- The additional features of claims 17-19, 38-40, 47-58, 61-64 are merely conventional as they relate to the use of the method for different antigens, to the addition of known agents for the improvement of rectal antigen administration and to modified adjuvants. These additional features do not result in an unexpected effect and would have been applied by the skilled person in his routine work.

**c) Industrial Applicability**

For the assessment of the present claims 1-45 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**d) Document D6**

This document discloses mucosal immunization with HIV-1 peptide vaccines. Mucosal and systemic cytotoxic T lymphocytes are induced as well as protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Cholera toxin adjuvant, while enhancing the response, was not essential. The peptides used are identical to those of the present application.

This document therefore, would appear to disclose or make obvious the subject-matter of claims 1-69.

However, the current assessment is based on the assumption that all claims enjoy priority rights from the priority document. The present priority date of 11.09.1997 is,



namely, before the publication date of D6 (17.02.1998). If it later turns out that the assumption is not correct, document D6 could become relevant.

## **Part VII**

- a) Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1, D2, D4 is not mentioned in the description, nor are these documents identified therein.
- b) The expression "herein incorporated by reference" or equivalents thereof (see pages 14 and 15) will have to be deleted in some cases when entering the national or regional phase (see e.g. the Guidelines for Examination in the EPO, C-II, 4.18). The reference to non-published patent applications will also have to be changed to published publication numbers throughout the application.
- c) Dependent claims 6 and 27 should have been changed to read "...a cytokine" instead of "...the cytokine" as the independent claims do not mention a cytokine.
- d) The statement on page 1, first paragraph has no bearing on the invention or its background art and should thus have been deleted as being irrelevant (Art. 6, Rule 9.1 (iv) PCT).

## **Part VIII**

- a) The groups of claims 8, 9, 10, 11 and 31, 32 respectively appear to have identical scope. This redundancy renders the set of claims unclear (Art. 6 PCT). Therefore, it would have appeared appropriate to delete claims 9, 10, 11 and 32.
- b) It is apparent from the description (see e.g. page 50) that IL-12 is only useful for improving protective mucosal CTL response in a mammal when it is mucosally administered. Claim 7 which encompasses systemic application of IL-12 is contradictory to this teaching and therefore does not meet the requirements of Art. 6 PCT.





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/19028

- c) The vague and imprecise statement ("spirit of invention") in the description on page 52 implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, PCT/GL/3 III, 4.3a).



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/00, 39/39, 38/19, 39/21, 39/145, 39/02, 39/002, 9/00 // C07K 14/16, (A61K 39/39, 38:19)</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/12563</b> <b>(43) International Publication Date:</b> 18 March 1999 (18.03.99)
<b>(21) International Application Number:</b> PCT/US98/19028 <b>(22) International Filing Date:</b> 11 September 1998 (11.09.98)  <b>(30) Priority Data:</b> 60/058,523 11 September 1997 (11.09.97) US 60/074,894 17 February 1998 (17.02.98) US  <b>(71) Applicant (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Box OTT, Bethesda, MD 20892 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BERZOFSKY, Jay, A. [US/US]; 5908 Bradley Boulevard, Bethesda, MD 20814-1107 (US). BELYAKOV, Igor M. [RU/US]; 10230 Wild Apple Circle, Gaithersburg, MD 20879 (US). DERBY, Michael, A. [US/US]; 11413 Herefordshire Way, Germantown, MD 20876 (US). KELSALL, Brian, L. [US/US]; 5030 Eskridge Terrace, N.W., Washington, DC 20016 (US). STROBER, Warren [US/US]; 8301 Whittier Boulevard, Bethesda, MD 20817 (US).		<b>(74) Agents:</b> KING, Jeffrey, J. et al.; Townsend and Townsend and Crew, 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> MUCOSAL CYTOTOXIC T LYMPHOCYTE RESPONSES			
<b>(57) Abstract</b>  The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

17/PRTS

5

MUCOSAL CYTOTOXIC T LYMPHOCYTE RESPONSESRelated Applications

10

The present application is a continuation-in-part application of, and claims the benefit under Title 35 of U.S. Provisional Application Nos. 60/058,523 filed on September 11, 1997, and 60/074,894 filed on February 17, 1998.

15

Technical Field

The present invention relates to methods and compositions for stimulating immune responses in mammals. More particularly, the invention relates to methods and compositions for stimulating mucosal immunity.

20

Background of the Invention

25

Many infectious pathogens, e.g., *HIV-1*, enter their mammalian hosts via a mucosal tissue prior to establishing a systemic infection. Veazey, et al., Science 280:427-431, 1998. Accordingly, vaccines capable of protecting against HIV should be capable of inducing long-term mucosal immune responses. A number of recent studies have shown that such immune responses require direct stimulation of mucosal tissues, and may be achieved with live attenuated virus, Cranage, et al., Virology 229:143-154, 1997, subunit SIV envelope Lehner, et al., Nature Medicine 2:767-775, 1996, HIV-recombinant viruses, including recombinant MVA 89.6 env (Belyakov et al., unpublished), or HIV peptide constructs Belyakov, et al., Proc. Nat. Acad. Sci. 95:1709-1714, 1998 (see also, Gallichan, et al., J. Exp. Med. 184:1879-1890, 1996; Cranage, et al., Virology 229:143-154, 1997; and Rosenthal, et al., Semin. Immunol. 9:303-314, 1997).

35

40

Numerous questions remain, however, concerning which vaccine candidates may afford the most effective protection against mucosal challenge with virus, and what

mechanisms may be involved in mediating protective immunity. While a number of studies have shown a role for CTL in protection against infections such as influenza that have a mucosal component (Taylor and Askonas, Immunology 58:417-420, 1986; Epstein et al., J. Immunol. 160:322-327, 1998; Kulkarni et al., J. Virol. 69:1261-1264, 1995), these reports have not established whether the CTL need to be in a local mucosal site to protect. Conversely, while other studies have shown the induction of CTL in the mucosa, they have not established that these cells have a role in protection (Gallichan and Rosenthal, J. Exp. Med. 184:1879-1890, 1996; Bennink et al., Immunology 35:503-509, 1978; Lohman et al., J. Immunol. 155:5855-5860, 1995); and Klavinskis, et al., J. Immunol. 157:2521-2527, 1996 J. Immunol. 155:5855-5860, 1995. Yet other studies have shown the induction by vaccines of protective immunity in the mucosa, but in the face of multiple immune responses, have not been able to sort out which responses are involved in protection (Lehner et al., Nature Medicine 2:767-775, 1996; Putkonen et al., J. Virol. 71:4981-4984, 1997; Miller et al., J. Virol. 71:1911-1921, 1997; Quesada-Rolander et al., AIDS Res Hwn Retroviruses 12:993-999, 1996; Bender et al., J. Virol. 70:6418-6424, 1996; Wang et al., Vaccine 15:821-825, 1997).

Thus, although the role of CTL in protection against mucosal infections has been of interest for decades, especially in the case of influenza virus, prior investigations have failed to identify fundamental mechanisms linking immune responses to protection. In this regard, because mucosal infection by virus induces a local IgA response, it has been too readily assumed that this response, and not a concomitant CTL response, was responsible for protection against viral infection through the mucosal route. However, the role of secretory IgA in neutralizing and protecting against mucosal HIV challenge is also not clear.

CTL are crucial mediators of immunity to intracellular microorganisms such as viruses as well as certain bacteria and protozoan parasites. CTL specifically recognize "non-self" antigenic peptides bound to major

histocompatibility complex (MHC) class I molecules on the surface of "target cells" and then kill the target cells expressing the non-self antigenic peptides. Non-self polypeptides from which the non-self peptides are derived can be a) proteins encoded by intracellular microbes, b) host-encoded proteins whose expression is induced by a microbe, or c) mutant host encoded proteins expressed by, for example, tumor cells.

Thus, generation of CTL responses in the inductive and the effector mucosal immune system may be important to establishing effective protective immunity to intracellular microbial pathogens that establish infection via the mucosal barriers. In some cases, administration of antigens via parenteral routes (subcutaneous, intramuscular, intravenous or intraperitoneal, for example) either fails to induce mucosal immunity or does so extremely inefficiently.

As noted above, previous reports of mucosal immune responses elicited by mucosal challenge with viruses have disclosed that the latter induces antiviral antibody responses, and in some cases CTL responses, in the intraepithelial lymphoid populations. Chen et al., J. Virol. 71:3431-3436, 1997; Sydora, et al., Cell Immunol. 167:161-169, 1996. However, it is not clear if either of such responses is relevant to protection against viral infection in general, or HIV infection in particular. Additional studies have suggested a role for CTL in protection against infections that involve the mucosa, such as influenza or respiratory syncytial virus, Taylor et al., Immunology 58:417-420, 1986; Epstein et al., J. Immunol. 160:322-327, 1998; Kulkarni et al., J. Virol. 69:1261-1264, 1995. However, these studies have not addressed the question of whether CTL must be present at the mucosal site of infection, or if their principal activity occurs systemically.

Accordingly, a need exists in the art to better define the roles and mechanisms of CTL in mediating immunity and to develop new tools for mediating immune protection against HIV and other pathogens, particularly by conferring

immune protection at mucosal sites where such pathogens initially proliferate.

#### Summary of the Invention

The present invention is directed to methods and compositions for inducing a protective mucosal CTL response in a subject. The methods of the invention involve administering either a soluble antigen itself, or a polynucleotide encoding the soluble antigen, to a mucosal surface. The soluble antigens can be full length, naturally occurring polypeptides or fragments (i.e., peptides) derived from them. Peptides to be administered can be any length less than that of the naturally occurring polypeptide. They can be, for example, five to one hundred amino acid residues long, preferably twenty to seventy five amino acid residues long, more preferably twenty five to sixty amino acid residues long and most preferably thirty to fifty amino acid residues long.

The soluble antigen is administered with an adjuvant at the mucosal site or without an adjuvant. Adjuvants can be, for example, cholera toxin (CT), mutant CT (MCT), *E. coli* heat labile enterotoxin (LT) or mutant LT (MLT). IL-12 and/or IFN $\gamma$  can be administered with the soluble antigen either in the presence or absence of an adjuvant. Alternatively, the two cytokines (IL-12 and/or IFN $\gamma$ ) can be administered systemically and separately from the soluble antigen which is administered mucosally, optionally with adjuvant. Mucosal routes of administration include IR, intranasal (IN), intragastric (IG), intravaginal (IVG) or intratracheal (IT).

Soluble antigens can be derived from pathogenic viruses (e.g., HIV-1, influenza virus or hepatitis A virus), bacteria (e.g., *Listeria monocytogenes*), protozoans (e.g., *Giardia lamblia*). Alternatively, the soluble antigen can be a tumor-associated antigen, e.g., prostate specific antigen produced by prostate tumor cells or tyrosinase produced by melanoma cells. Peptide antigens can be cluster peptide vaccine constructs (CLUVAC). For example, an HIV-1 CLUVAC can include one or more of the following sequences:  
EQMHEDIISLWDQSLKPCVKRIQRGPGRAFVTIGK (SEQ ID NO:1),



KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTIGK (SEQ ID NO:2),  
RDNWRSELYKYKVVKIEPLGVAPTRIQRGPGRAFVTIGK (SEQ ID NO:3),  
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK (SEQ ID  
NO:4), DRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK (SEQ ID  
5 NO:5), DRVIEVVQGAYRAIRRIQRGPGRAFVTIGK (SEQ ID NO:6),  
AQGAYRAIRHIPRRIRRIQRGPGPRAFVTIGK (SEQ ID NO:7),  
EQMHEDIISLWDQSLKPCVKRIHIGPGRAFYTTKN (SEQ ID NO:8),  
KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9),  
RDNWRSELYKYKVVKIEPLGVAPTRIHIHIGPGRAFYTTKN (SEQ ID NO:10),  
10 AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN (SEQ ID  
NO:11), DRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN (SEQ ID  
NO:12), DRVIEVVQGAYRAIRRIHIGPGRAFYTTKN (SEQ ID NO:13) or  
AQGAYRAIRHIPRRIRRIHIGPGRAFYTTKN (SEQ ID NO:14).

Preferably, the CLUVAC includes the amino acid  
15 sequence of SEQ ID NO:2, SEQ ID NO:9 or SEQ ID NO:12.  
Antigenic peptides can be longer than the length specified  
by the SEQ ID NOS. recited herein, i.e., the peptide can be  
extended by adding one or more (e.g., 5, 10, 15, 20) amino  
acids at the amino and/or carboxy termini of the peptide  
20 with any given SEQ ID NO.

The invention also encompasses methods for inducing  
a protective mucosal CTL response in a subject in which the  
soluble antigen is delivered IR. Preferably, the level of CTL  
activity induced by IR immunization is at least 10% greater  
25 than that induced by other routes of mucosal administration  
(e.g., IN). More preferably, mucosal CTL activity induced by  
IR immunization is at least 2-fold, more preferably, at least  
5-fold, and most preferably, at least 10-fold greater than  
that induced by other routes of mucosal immunization (e.g., IN  
30 or IG).

Subjects to which the methods of the invention are  
applied are mammals, e.g., humans, non-human primates, cats or  
mice.

Also provided within the invention are immunogenic  
35 compositions for inducing a protective mucosal CTL response in  
a subject which are adapted for intrarectal administration.  
The compositions comprise a purified soluble antigen  
formulated for intrarectal delivery to the rectum, colon,

sigmoid colon, or distal colon. They may be formulated as a rectal enema, foam, suppository, or topical gel and generally comprise a base, carrier, or absorption-promoting agent adapted for intrarectal delivery.

5 In more detailed aspects, the immunogenic compositions of the invention may include a rectal emulsion or gel preparation, preferably wherein the soluble antigen is admixed with a homogenous emulsion or gel carrier, eg., a polyoxyethylene gel. Alternatively, the soluble antigen may  
10 be admixed with a rectally-compatible foam.

In other preferred aspects, the immunogenic compositions of the invention are formulated in a suppository. The suppository is comprised of a base or carrier specifically adapted for intrarectal delivery of the antigen. Preferred  
15 bases may be selected from a polyethyleneglycol, witepsol H15, witepsol W35, witepsol E85, propyleneglycol dicaprylate (Sefsol 228), Miglyol 810, hydroxypropylcellulose-H (HPC), or carbopol-934P (CP). More preferably, the suppository comprises at least two base materials to optimize structural  
20 and delivery performance. In other aspects, the suppository includes a stabilizing agent to minimize intrarectal degradation of the soluble antigen.

To optimize intrarectal delivery, the immunogenic compositions of the invention also preferably include an  
25 absorption-promoting agent, for example a surfactant, mixed micelle, enamine, nitric oxide donor, sodium salicylate, glycerol ester of acetoacetic acid, cyclodextrin or beta-cyclodextrin derivative, or medium-chain fatty acid.

In yet additional aspects of the invention,  
30 immunogenic compositions are provided which include an adjuvant which enhances the CTL response. Suitable adjuvants are detoxified bacterial toxins, for example detoxified cholera toxin (CT), mutant cholera toxin (MCT), mutant- E. coli heat labile enterotoxin, and pertussis toxin.

35 Preferably, the adjuvant is conjugated to a mucosal tissue or T cell binding agent, such as protein A, an antibody that binds a mucosal tissue- or T-cell-specific protein, or a ligand or peptide that binds a mucosal tissue- or T-cell-

specific protein. In more preferred aspects, the adjuvant is a recombinant cholera toxin (CT) having a B chain of CT substituted by protein A conjugated to a CT A chain, which exhibits reduced toxicity and enhances mucosal tissue binding mediated by protein A. Alternatively the adjuvant may be conjugated to a protein or peptide that binds specifically to T cells, for example by binding CD4 or CD8 (eg., the HIV V3 loop or a T cell-binding peptide fragment of the HIV V3 loop).

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present application, including definitions, will control. In addition, the materials, methods, and examples described herein are illustrative only and not intended to be limiting.

Other features and advantages of the invention, e.g., prevention of viral or other infectious diseases, will be apparent from the following detailed description, from the drawings and from the claims.

#### Brief Description of the Drawings

Fig. 1 is a series of line graphs showing the results of a CTL assay. IR HIV-1 peptide immunization induced long lasting mucosal and systemic CTL activity.

Fig. 2 is a series of line graphs showing the results of a CTL assay. CT enhanced (but was not essential) for induction of CTL by IR administration of antigenic peptide.

Fig. 3 is a series of line graphs showing the results of a CTL assay. CTL induced by IR immunization with an HIV-1 gp160 peptide specifically lysed target cells transfected with and expressing an HIV-1 gp160 gene.

Fig. 4 is a series of line graphs showing the results of a CTL assay which indicated that IR induction of CTL was IL-12 dependent.

Fig. 5 is a bar graph showing that IR immunization protects against IR challenge with *HIV-1* gp160 expressing recombinant vaccinia virus.

Fig. 6A is a line graph showing the results of a CTL assay using SP cells obtained from animals six months after IR immunization with an antigenic peptide.

Fig. 6B is a line graph showing the results of a CTL assay using SP cells obtained from animals six months after intranasal (IN) immunization with antigenic peptide.

Fig. 7A is a bar graph showing the results of a CTL assay using PP as effector cells.

Fig. 7B is a bar graph showing the results of a CTL assay using SP cells as effector cells. PP and SP cells were obtained from animals thirty five days after mucosal (IR, IN, IG) or systemic (subcutaneous (SC)) immunization with an antigenic peptide.

Fig. 8A is a bar graph showing the results of a CTL assay using effector cells from wild-type BALB/c mice.

Fig. 8B is a bar graph showing the results of a CTL assay using effector cells from BALB/c mice which lack the ability to produce functional IFN $\gamma$ . These experiments show the dependence of IR induction of CTL on IFN $\gamma$ .

Fig. 9A is a line graph showing the results of a CTL assay using PP as effector cells.

Fig. 9B is a line graph showing the results of a CTL assay using SP cells as effector cells. PP and SP cells were obtained from BALB/c mice thirty five days after IR immunization with either antigenic peptide, CT and IL-12 (composition A) or antigenic peptide and CT (without IL-12; composition B).

Figs. 10A and 10B demonstrate that IR immunization with PCLUS3-18IIIB or PCLUS3-18MN induces both Peyer's patch (panel A) and spleen (panel B) long-lasting immunity. However the levels of the induction of CTL are different. Killing of P18IIIB-I10 (closed squares) or P18MN-T10 peptide-pulsed targets (closed circles) is compared with killing of unpulsed targets (open squares or circles). In both panel A and panel B, SEM of triplicate were all <5% of the mean.

Fig. 11 demonstrates that protection induced by mucosal immunization with HIV-1 peptide vaccine is specific. On day 35, mice were challenged intrarectally with  $2.5 \times 10^7$  plaque-forming units (pfu) of vaccinia virus expressing gp 160IIB (vPE16) or with  $2.5 \times 10^7$  pfu of vaccinia virus expressing  $\beta$ -galactosidase (vSC8). Bars = SEM of five mice per group. The difference is significant at  $P < 0.01$  by Student's test.

Fig. 12 demonstrates that protection induced by mucosal immunization with HIV-1 peptide vaccine is long-lasting. On day 35 or 6 months after the start of the immunization, mice were challenged intrarectally with  $2.5 \times 10^7$  pfu of vaccinia virus expressing gp 160IIIB. Bars = SEM of five mice per group. The difference is significant at  $P < 0.01$  by Student's test.

Fig. 13 demonstrates that protection induced by mucosal immunization with HIV-peptide is dependent on CD8 positive T-cells. BALB/c mice were treated IP with 0.5 mg monoclonal anti-CD8 antibody (clone 2.43, NIH Frederick, MD) one day before and after each immunization and also two days before and three days after the challenge with vPE16. Mice were challenged intrarectally with  $2 \times 10^7$  pfu of vPE16 vaccinia virus expressing gp 160IIIB.

Figs. 14A and 14B demonstrate that mucosal immunization with HIV-1 peptide induces mucosal CTL responses and stimulates protective immunity against intrarectal recombinant HIV-1 vaccinia challenge. Figure 14A depicts induction of the mucosal and systemic CTL responses by different routes of immunization with synthetic peptide HIV vaccine. Killing of peptide-pulsed targets (closed bars) is compared with killing of unpulsed targets (open bars) at an effector-to-target ratio of 50:1. Panel A depicts results or immunizing on day 35 (IR or SC--bar 1, no immunogen; bar 2, SC; bar 3, IR) BALB/c mice challenged intrarectally with  $2.5 \times 10^7$  plaque-forming units (pfu) of vaccinia virus expressing gp 160IIIB.

Figs. 15A and 15B demonstrate enhancement of the mucosal (Fig. A) and systemic (Fig. B) CTL responses to HIV-1

peptide by the mucosal (not systemic) treatment with rmIL-12. BALB/c mice were treated by the IP route (right panels) or IR route (left panels) with 1 $\mu$ g of the rmIL-12 each day of the IR immunization with PCLUS3-18IIIB (50  $\mu$ g/mice). On day 35 HIV-specific Peyer's patch CTL (Fig. 15A) and spleen CTL (Fig. 15B) were studied.

Fig. 16 demonstrates that mucosal treatment with rmIL-12 in DOTAP along with HIV peptide vaccine enhances protection against mucosal challenge with vaccinia virus expressing gp160IIIB (vPE16). Five mice per group were immunized IR on days 0, 7, 14 and 21 with no immunogen (bar 1), with 50  $\mu$ g PCLUS3-18IIIB alone (bar 2), or with peptide plus 1  $\mu$ g rmIL-12 in DOTAP (bar 3), and challenged on day 35 intrarectally with 5 X 10<sup>7</sup> pfu of vaccinia virus expressing gp 160IIIB. Viral pfu in the ovaries were determined six days later.

Figs. 17A and 17B demonstrate that IL-12 cannot act directly in the induction of mucosal CD8+ CTL in the absence of IFN $\gamma$ . IFN $\gamma$ <sup>-/-</sup> mice (BALB/c background) were immunized IR with the rmIL-12 (1  $\mu$ g/mouse) + DOTAP together with peptide. On day 35 HIV-specific Peyer's patch CTL (Fig. 17A) and spleen CTL (Fig. 17B) were studied. Killing of P18IIIB-I10 pulsed targets by effector cells from immunized IFN $\gamma$ <sup>-/-</sup> mice (closed squares) or conventional BALB/c mice (closed circles) is compared with killing of unpulsed targets (open squares or circles).

### Detailed Description

#### A. INDUCTION OF MUCOSAL IMMUNITY

The present invention is based on the discovery that IR administration of a peptide, e.g., a synthetic multideterminant HIV-1 gp160 envelope glycoprotein peptide, to a mucosal surface can induce an antigen-specific, protective CTL response in the mucosal immune system, even in the absence of a mucosal adjuvant.

The exemplary synthetic multideterminant peptides (CLUVAC) are composed of subregions containing epitopes that evoke some or all of (a) a helper T cell response, (b) a CTL

response and (c) a high titer of neutralizing antibodies in multiple hosts of a given species expressing a broad range of MHC haplotypes. IR immunization with the *HIV-1* CLUVAC PCLUS3-18IIIB (SEQ ID NO:2), and the mucosal adjuvant CT induced peptide-specific CTL in both the inductive (PP) and the effector (LP) sites of the mucosal immune system, as well as in systemic lymphoid tissue, i.e., SP. In contrast, systemic immunization with peptide vaccine produced *HIV-1* peptide-specific CTL only in the SP.

IR immunization induced long-lasting protective immune responses. For example, antigen-specific CTL were found in both mucosal and systemic sites 6 months after immunization. IR immunization with the antigenic peptide elicited significantly stronger CTL responses than IN immunization with the same peptide. While IR administration with PCLUS3-18IIIB (SEQ ID NO:2) induced a significant response when administered alone, the response was enhanced by the inclusion of CT. The CTL were CDB+ T lymphocytes restricted by MHC class I molecules, recognizing MHC class I positive target cells either endogenously expressing *HIV-1* gp160 or pulsed with an appropriate gp160 peptide. Induction of both mucosal and systemic CTL response by IR immunization was IL-12-dependent, as shown by inhibition of induction of CTL in mice treated i.p. with anti-IL-12 antibody. Furthermore, inclusion of IL-12 in the composition of antigenic peptide and CT used for IR immunization resulted in enhanced mucosal and systemic CTL responses relative to the responses elicited by antigenic peptide and CT without IL-12. The dependence on IFN $\gamma$  of mucosal and systemic CTL generation following IR immunization was demonstrated by the absence of such responses in mice which lack the ability to produce functional IFN $\gamma$ , e.g., as the result of a premature stop codon in the IFN $\gamma$ -encoding gene. The stop-codon mutation causes the gene to encode a truncated protein lacking the activity of IFN $\gamma$ .

IR immunization with PCLUS3-18IIIB (SEQ ID NO:2) protected mice against an IR challenge with a recombinant vaccinia virus expressing *HIV-1* IIIB gp160. Thus, an *HIV-1*

peptide induced CTL responses in the mucosal and systemic immune systems after IR immunization and protected against mucosal challenge with virus expressing *HIV-1* gp160.

The immunization method of the invention is useful to induce a mucosal CTL response to any soluble antigen. Accordingly, the invention provides a new method for vaccine administration to elicit immunologic protection against viruses that enter through mucosal barriers, including *HIV-1*. The method can also be applied to achieving protection from infection by certain bacteria (e.g., *L. monocytogenes*) and protozoa (e.g., *G. lamblia*) that establish infection via mucosae. In addition, since mucosal immunization results in systemic generation of CTL activity, the protocol can also be useful in prevention of infection by microorganisms that enter through non-mucosal routes. The method is also useful for immunotherapy of infections that are mucosally or non-mucosally established. Finally, the methods can be utilized for immunotherapy of cancer, both in the region of and remote from a mucosal surface.

#### B. METHODS OF IMMUNIZATION

The invention features methods for protecting subjects from infection by intracellular microorganisms such as viruses as well as intracellular bacteria and protozoans. The methods involve induction of CTL responses specific for antigenic peptides derived from proteins encoded by genes of relevant microbes and expressed in association with MHC class I molecules on the surface of infected cells. This is achieved by delivery of an appropriate soluble antigen to a mucosal surface, e.g., rectal, vaginal, nasopharyngeal, gastric or tracheal mucosae. Relevant microorganisms include but are not restricted to those that enter their hosts via mucosal barriers, e.g. *HIV-1*, influenza virus, enteric viruses such as rotaviruses, hepatitis A virus, papilloma virus, feline immunodeficiency virus, feline leukemia virus, simian immunodeficiency virus, intracellular bacterial pathogens, e.g., *L. monocytogenes* and mycobacteria such as *M. tuberculosis* and *M. leprae*. Since the responses elicited by



mucosal immunization occur in the systemic as well as the mucosal immune system, the methods can also be applied to protection from infection by intracellular pathogens that enter their hosts via non-mucosal (e.g., *HIV-1* in some scenarios such as a "stick" by a contaminated syringe needle, rabies virus and malarial protozoans) as well as mucosal routes. In light of the above considerations, immunization via mucosae can also be used for immunotherapy of intracellular infections.

Finally, the mucosal immunotherapy of the invention can be applied to subjects with cancer, particularly, but not limited to, those with solid tumors in the region of the relevant mucosa, e.g., colonic, rectal, bladder, ovarian, uterine, vaginal, prostatic, nasopharyngeal, lung or certain melanoma tumors. Tumor immunity is substantially mediated by CTL with specificity for tumor associated peptides (e.g., prostate specific antigen peptides in prostatic cancer, carcinoembryonic antigen peptides in colon cancer, human papilloma virus peptides in bladder cancer and MART1, gp100 and tyrosinase peptides in melanoma) (Rosenberg et al. (1994) *J.N.C.I.* 76:1159; Kawakami et al. (1994) *Proc. Natl. Acad. Sci. USA.* 91:3515) bound to MHC class I molecules on the surface of tumor cells.

#### B.1 — Antigenic Polypeptides

A soluble antigen to be administered according to the invention can be any soluble carbohydrate or peptide antigen, e.g., one containing all or part of the amino acid sequence of a peptide which is naturally expressed in association with a MHC class I molecule on the surface of a cell infected with relevant microbe or expressed on a tumor cell. In the case of infected cells, the cell surface expressed peptide is derived from a protein either encoded by genes of the infectious agent or whose expression is induced by the infectious agent. Thus, the soluble antigen can be a full length, naturally occurring polypeptide, e.g., full length *HIV-1* gp160 or gp120 or an antigenic fragment thereof.

Antigen-specific recognition by CTL involves interactions between components of the antigen-specific T cell receptor on the surface of the CTL and residues on both the antigenic peptide and the MHC class I molecule to which the peptide is bound. Thus the soluble antigen can also be a fragment (i.e., a peptide) of the naturally occurring polypeptide that is either (a) itself capable of binding to MHC class I molecules of multiple haplotypes on the surface of antigen presenting cells (APC) and stimulating CD8+ T cell responses in subjects expressing these MHC class I haplotypes or (b) which can be proteolytically processed by APC into fragments with these properties. Ways of establishing the ability of a candidate peptide to stimulate a CTL response in the context of multiple MHC class I haplotypes are well known to one of ordinary skill in the art and are amply described in co-pending U.S. patent application 08/060,988 incorporated herein by reference in its entirety.

Antigenic peptides can be engineered to bind to MHC class II molecules of multiple haplotypes and will be recognized by CD4+ helper T cell precursor cells of subjects expressing multiple MHC class II haplotypes. Ways of establishing the ability of a candidate peptide to stimulate a helper T cell response in the context of multiple MHC class II haplotypes are well known to one of ordinary skill in the art and are amply described in co-pending U.S. patent application 08/060,988 incorporated herein by reference in its entirety.

In addition, antigenic peptides, can contain epitopes that elicit neutralizing antibodies, i.e., those that bind to the relevant microbe or a cell infected with the microbe and neutralize or kill it. Ways of establishing these properties of a candidate peptide are well known to one of ordinary skill in the art and are amply described in copending U.S. patent application 08/060,988 incorporated herein by reference in its entirety.

Antigenic peptides can also elicit antibodies that induce antibody-dependent cellular cytotoxicity (ADCC) of cells infected by the appropriate microbe or tumor cells expressing at their surface the protein from which the antigenic peptide

was derived. ADCC is a protective mechanism by which specialized cells of the immune system (K cells) recognize the Fc portion of IgG antibody molecules bound to the surface of a target cell and lyse the relevant target cell. Sera, or other body fluids such as rectal lavages, from test subjects mucosally immunized with a candidate peptide can be tested for their ability to mediate ADCC by methods known to an ordinary artisan. A standard cell mediated lympholysis (CML) assay is used. Briefly, a source of lymphoid ADCC effector cells (e.g., peripheral blood mononuclear cells (PBMC) or SP cells) is incubated *in vitro* with target cells expressing the above described cell surface protein in the presence of various dilutions of test sera. Lysis of the target cells, which can be measured by the release of a detectable label ( $^{51}\text{Cr}$ , for example) from prelabeled target cells, is an indication of the presence of ADCC inducing antibodies in the test serum.

Peptides of the invention can be cluster peptide vaccine constructs (CLUVAC). A CLUVAC is a chimeric peptide containing a) a subregion with multiple overlapping helper T cell activating epitopes that can be presented by multiple MHC class II molecules (a cluster peptide), b) a subregion with a CTL activating epitope and c) a subregion that elicits the production of a neutralizing antibody. The peptide sequences containing these epitopes can be derived from different parts of a microbial or tumor associated polypeptide. Alternatively, the CTL inducing and antibody neutralizing epitopes can be located in one subregion of an antigen and the helper epitope(s) can be in a second subregion. CLUVAC and their design are extensively described in co-pending U.S. patent application 08/060,988 incorporated herein by reference in its entirety.

HIV-1 CLUVAC can include the following sequences:

EQMHEDIISLWDQSLKPCVKRIQRGPGRAFTIGK (SEQ ID NO:1)

KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFTIGK (SEQ ID NO:2)

RDNRSELYKVKVVKIEPLGVAPTRIQRGPGRAFTIGK (SEQ ID NO:3)

AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFTIGK (SEQ ID NO:4)

DRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFTIGK (SEQ ID NO:5)

DRVIEVVQGAYRAIRRIQRGPGRAFTIGK (SEQ ID NO:6)

AQGAYRAIRHIPRRIRRIQRGPGRAFVTIGK (SEQ ID NO:7)  
 EQMHEDIISLWDQSLKPCVKRIHIGPGRAFYTTKN (SEQ ID NO:8)  
 KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9)  
 RDNWRSELYKYKVVKIEPLGVAPTRIHIGPGRAFYTTKN (SEQ ID NO:10)  
 5 AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN (SEQ ID  
 NO:11)  
 DRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN (SEQ ID NO:12)  
 DRVIEVVQGAYRAIRRIHIGPGRAFYTTKN (SEQ ID NO:13)  
 AQGAYRAIRHIPRRIRRIHIGPGRAFYTTKN (SEQ ID NO:14)

10 It is possible, for example, to link a particular  
 cluster peptide to any peptide containing a CTL and/or  
 neutralizing antibody epitope. Examples of cluster peptides  
 include: cluster peptide 1 whose amino acid sequence  
 (EQMHEDIISLWDQSLKPCVK) (SEQ ID NO:17) is the first 20 amino  
 15 acids of the *HIV-1* CLUVAC with SEQ ID NO:1; cluster peptide 3  
 whose amino acid sequence (KQIINMWQEVGKAMYAPPISGQIR) (SEQ ID  
 NO:18) is the first 24 amino acids of the *HIV-1* CLUVAC with  
 SEQ ID NO: 2; cluster peptide 4 whose amino acid sequence  
 (RDNWRSELYKYKVVKIEPLGVAPT) (SEQ ID NO:19) is the first 24  
 20 amino acids of the *HIV-1* CLUVAC with SEQ ID NO:3; and cluster  
 peptide 6 whose amino acid sequence  
 (AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLER) (SEQ ID NO:20) is the  
 first 33 amino acids of the *HIV-1* CLUVAC with SEQ ID NO:4.

Of particular interest are peptides containing the  
 25 amino acid sequences of SEQ ID NO:2, SEQ ID NO:9 and SEQ ID  
 NO:12. Mucosal responses to the first (PCLUS3-18IIIB) are  
 extensively characterized in the Examples presented *infra*.  
 PCLUS3-18MN (SEQ ID NO:9) and PCLUS6.1-18MN (SEQ ID NO:12)  
 have been tested in human clinical trials. The CTL epitope  
 30 within PCLUS3-18IIIB (SEQ ID NO:2) is the amino acid sequence  
 RIQRGPGRAFVTIGK (SEQ ID NO:15).

In some instances, mucosal adjuvants are co-  
 administered at the mucosal tissue site with the soluble  
 antigens. Such adjuvants include, but are not limited to,  
 35 detoxified bacterial toxins, for example detoxified cholera  
 toxin (CT), *E. coli* heat labile toxin (LT), mutant CT (MCT)  
 (Yamamoto et al. J. Exp. Med. 185:1203 (1997); Yamamoto et  
 al. Proc. Natl. Acad. Sci. USA 58:5267 (1997); Douce et al.

Infect. Immunity 65:2821 (1997)), mutant E. coli heat labile toxin (MLT) (Di Tommaso et al. Infect. Immunity 64:974 (1996); Partidos et al. Immunology 89:83 (1996), and pertussis toxin. MCT and MLT contain point mutations that substantially ablate toxicity without substantially compromising adjuvant activity relative to that of the parent molecules. In other preferred embodiments, the adjuvant is modified for increased binding to mucosal tissues and/or T-cells. Thus, in one aspect of the invention, CT or other bacterial toxins are conjugated to a mucosal tissue binding agent, such as protein A, an antibody that binds a mucosal tissue- or T-cell-specific protein (eg., a receptor), or a ligand or peptide that binds a mucosal tissue- or T-cell-specific protein (eg., CD4 or CD8). For example, the B chain of CT may be substituted by protein A, conjugated to the CT A chain, to eliminate toxicity and enhance mucosal tissue binding mediated by protein A. Alternatively, the HIV V3 loop which binds CD4 on T cells may be conjugated to the adjuvant to enhance delivery to T cells.

The CTL augmenting cytokines, eg., IL-12 and IFN $\gamma$ , are, in some instances, either administered systemically or; preferably, coadministered at the mucosal tissue site with the soluble antigen.

Variants of disclosed antigenic peptides can contain different amino acids (preferably conservative changes) from the parental molecules but retain the biological activity of the parental molecules, e.g., the ability to induce specific CTL responses subsequent to mucosal immunization. Such variants can be synthesized by standard means, and are readily tested in assays known to those in the art. Antigenic polypeptides are typically longer than the length of the nominal SEQ ID NOS. recited herein, i.e., the polypeptide can be extended by adding amino acids to the amino or carboxy termini of the peptide defined by any given SEQ ID NO.

Peptides and polypeptides of the invention will also include those described above but modified for *in vivo* use by:

(a) chemical or recombinant DNA methods to include mammalian signal peptides (Lin et al., J. Biol. Chem. 270:14255 (1995)) or the bacterial peptide, penetratin (Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864 (1991)), that will serve to direct the peptide across cell and cytoplasmic membranes and/or traffic it to the endoplasmic reticulum (ER) of antigen presenting cells (APC), e.g., dendritic cells which are potent CTL inducers;

(b) addition of a biotin residue which serves to direct the polypeptides or peptide across cell membranes by virtue of its ability to bind specifically to a translocator present on the surface of cells (Chen et al., Analytical Biochem. 227:168 (1995));

(c) addition at either or both the amino- and carboxy-terminal ends, of a blocking agent in order to facilitate survival of the relevant polypeptide or peptide *in vivo*. This can be useful in those situations in which the termini tend to be degraded ("nibbled") by proteases prior to cellular or ER uptake. Such blocking agents can include, without limitation, additional related or unrelated peptide sequences that can be attached to the amino and/or carboxy terminal residues of the polypeptide or peptide to be administered. This can be done either chemically during the synthesis of the peptide or by recombinant DNA technology (see Section 3.3 *infra*). Alternatively, blocking agents such as pyroglutamic acid or other molecules known to those of average skill in the art can be attached to the amino and/or carboxy terminal residues, or the amino group at the amino terminus or carboxyl group at the carboxy terminus replaced with a different moiety. Likewise, the polypeptides or peptides can be covalently or noncovalently coupled to pharmaceutically acceptable "carrier" proteins prior to administration.

Also of interest are peptidomimetic compounds based upon the amino acid sequence of the peptides of the invention. Peptidomimetic compounds are synthetic compounds having a three-dimensional structure (i.e. a "peptide motif") based upon the three-dimensional structure of a selected peptide. The peptide motif provides the peptidomimetic compound with

the activity of binding to MHC molecules of multiple haplotypes and activating CD8<sup>+</sup> and CD4<sup>+</sup> T cells from subjects expressing such MHC molecules that is the same or greater than the activity of the peptide from which the peptidomimetic was derived. Peptidomimetic compounds can have additional characteristics that enhance their therapeutic application such as increased cell permeability, greater affinity and/or avidity and prolonged biological half-life. The peptidomimetics of the invention typically have a backbone that is partially or completely non-peptide, but with side groups identical to the side groups of the amino acid residues that occur in the peptide on which the peptidomimetic is based. Several types of chemical bonds, e.g. ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics.

## B.2 In vivo methods to deliver soluble antigens to mucosae of a subject

In methods of the invention that induce mucosal CTL responses, a soluble antigen is delivered to antigen presenting cells of the inductive mucosal immune system (e.g., PP of the intestine). Delivery involves administering to a subject either the soluble antigen itself, e.g., an antigenic peptide, an expression vector encoding the soluble antigen, or cells transfected or transduced with the vector.

### *B.2.1 Administration of soluble antigen*

Soluble antigens can be delivered to the mucosal immune system of a mammal using techniques substantially the same as those described *infra* for delivery to human subjects. Examples of appropriate mammals include but are not restricted to humans, non-human primates, horses, cattle, sheep, dogs, cats, mice, rats, guinea pigs, hamsters, rabbits and goats.

A soluble antigen of the invention can be delivered to the mucosal immune system of a human in its unmodified state, dissolved in an appropriate physiological solution,

e.g., physiological saline. Alternatively, it can be modified as detailed in Section B.1 in order to facilitate transport across cell and/or intracellular membranes and to prevent extracellular or intracellular degradation. Its transport across biological membranes can also be enhanced by delivering it encapsulated in liposomes using known methods (Gabizon et al., Cancer Res. 50:6371 (1990); Ranade, J. Clin. Pharmacol. 29:685 (1989)) or an appropriate biodegradable polymeric microparticle (also referred to as a "microsphere", "nanosphere", "nanoparticle, or "microcapsule"). Naturally, it is desirable that the soluble antigens be selectively targeted to the mucosae. This can be achieved by contacting the soluble antigens directly with the relevant mucosal surface, e.g., by IR, IVG, IN, intrapharyngeal (IPG) or IT infusion or implantation. CTL activity (systemic or mucosal) induced by IR immunization can be two-fold, preferably five-fold, more preferably twenty-fold, even more preferably fifty-fold and most preferably two hundred-fold greater than that induced by IN immunization.

Soluble antigens of the invention can be delivered in liposomes into which have been incorporated ligands for receptors on relevant cells (e.g., dendritic cell or macrophage APC) or antibodies to cell-surface markers expressed by these cells. Thus, for example, an antibody specific for a dendritic cell surface marker can direct liposomes containing both the anti-dendritic cell antibody and the relevant soluble antigen to dendritic cells.

The soluble antigens can be administered mucosally either alone or together with a mucosal adjuvant. Suitable adjuvants include, but are not restricted to, CT, MCT and MLT. IL-12 and/or IFN $\gamma$  can also be administered to the subject. Thus, a soluble antigen can be administered with an adjuvant, with IL-12 (in the absence of an adjuvant), with IFN $\gamma$  (in the absence of an adjuvant), with both IL-12 and IFN $\gamma$  (in the absence of an adjuvant), with an adjuvant and IL-12, with an adjuvant and IFN $\gamma$ , or with an adjuvant and both IL-12 and IFN $\gamma$ . The IL-12 and IFN $\gamma$  can be administered systemically or co-administered mucosally with the peptide. When the soluble



antigen is administered encapsulated in liposomes or microparticles, the IL-12 and/or IFN $\gamma$  can be co-incorporated into the same liposomes/microparticles or incorporated into separate liposomes/microparticles. Alternatively, the cytokines can be administered in a free, soluble form. Examples of other cytokines that can be used, singly or in combination, are granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), or tumor necrosis factor  $\alpha$  (TNF $\alpha$ ). These and other immunopotentiating cytokines are administered as discussed above for IL-12 and IFN $\gamma$ . Administration can be single or multiple (two, three, four, five, six, eight or twelve administrations, for example). Where multiple, they can be spaced from one day to one year apart. When using peptides without a helper T-cell epitope, it can be necessary to carry out such multiple administrations.

In preferred aspects of the invention formulations of soluble antigen are prepared for intrarectal administration (i.e., delivery to the rectum, colon, sigmoid colon, or distal colon), eg., by formulating the soluble antigen in a rectal enema, foam, suppository, or topical gel. These rectal delivery formulations are adapted for improved delivery, stability, and/or absorption in the rectum, eg., by combining the soluble antigen with one or more known intrarectal delivery base or carrier materials, intrarectal absorption-promoting materials, and/or stabilizers.

Preferred base formulations for rectal delivery of soluble antigen within the methods of the invention include hydrophilic and hydrophobic vehicles or carriers such as those commonly used in formulating suppositories and rectal emulsion or gel preparations. Thus, emulsion vehicles are used which incorporate soluble antigen in an oil/water emulsion suitable for intrarectal administration. Alternatively, gel formulations are provided which incorporate the soluble antigen in a homogenous gel carrier, for example a polyoxyethylene gel such as polyoxyethylene(20)cetyether(BC-20TX). When the antigen is formulated in a rectally compatible foam, a non-CFC propellant foam is preferred.

Preferred carriers or delivery vehicles for use within the invention are conventional suppository base materials that are adapted for intrarectal use, such as polyethyleneglycols. Exemplary polyethyleneglycols known and available in art include PEG 400, PEG 1500, PEG 2000, PEG 4000 or PEG 6000. Preferred bases in this context include witepsol H15, witepsol W35, witepsol E85. These are selected for their desired lipophilic and/or hydrophilic properties, and are often selected to form a multiple layer suppository with both lipophilic and hydrophilic base layers. Preferred lipophilic base materials are macrogols of low molecular weight. Particular examples of suitable lipophilic bases include propyleneglycol dicaprylate (Sefsol 228) and Miglyol 810. A preferred hydrophilic base is PEG, eg., PEG 400. In one formulation useful within the invention, hydroxypropylcellulose-H (HPC) and/or carbopol-934P (CP) are used as bases for an inner suppository layer, and a witepsol base is used for the outer layer.

Crystalline cellulose or other common stabilizing agents can be added in selected amounts (eg., 30-60% by weight) to the base to promote sustained release.

Selection of base materials, stabilizers, and absorption-promoting agents for formulating intrarectal delivery compositions, particularly suppositories, is determined according to conventional methods, eg., based on melting and drop rates, breaking hardness, disintegration and special breaking times, spreading properties, and diffusion rates. Preferred values of these various properties are known and can be readily determined to adjust antigen formulations to be suitable for intrarectal use. In particular, appropriate values for formulating a time-release suppository having appropriate structural and chemical properties for rectal delivery are known or readily ascertained. In this context, conventional additives, eg., softeners such as neutral oils, Estasan, etc. may be included to optimize consistency, rate of delivery and other characteristics of the formulation.

In formulating mucosal delivery compositions, it is also desired to include absorption-promoting agents to enhance delivery of the soluble antigen and, optionally the CTL-stimulatory cytokine, to the mucosal surface. A variety of absorption promoting agents (i.e., agents which enhance release or diffusion of the antigen and/or CTL-stimulatory cytokine from the delivery vehicle or base, or enhance delivery of the antigen and/or CTL-stimulatory cytokine to the mucosal tissue or T-cells, for example by enhancing membrane penetration) are known in the art and are useful in mucosal delivery formulations of the invention, eg., for inclusion in intrarectal delivery formulations, particularly suppositories. These include, but are not limited to, surfactants (eg., tween 80), mixed micelles, enamines, nitric oxide donors (eg., S-nitroso-N-acetyl-DL-penicillamine, NOR1, NOR4--which are preferably co-administered with an NO scavenger such as carboxy-PITO or doclofenac sodium), sodium salicylate, glycerol esters of acetoacetic acid (eg., glyceryl-1,3-diacetoacetate or 1,2-isopropylideneglycerine-3-acetoacetate) and other release-diffusion/absorption-promoting agents adapted for mucosal delivery.

Absorption-promoting agents useful within the invention include a variety of compounds specifically adapted for intrarectal use. In this context, the rate and extent of rectal drug absorption are often lower than with oral absorption, possibly an inherent factor owing to the relatively small surface area available for drug uptake. In addition, the composition of rectal formulations (solid vs liquid, nature of the suppository base) is an important factor in the absorption process. This relationship between formulation and drug uptake has been clearly demonstrated. Thus, coadministration of absorption-promoting agents (eg., surfactants, sodium salicylate, enamines) represents a key approach towards optimizing rectal drug absorption.

Rectal drug delivery in a site- and rate-controlled manner using suppositories, enemas, osmotic pumps, or hydrogel formulations provides a range of options for manipulating mucosal delivery, eg., controlling concentrations, time-

release, and immunogen-drug effects. Absorption from aqueous and alcoholic solutions may occur very rapidly, but absorption from suppositories is generally slower and very much dependent on the nature of the suppository base, the use of surfactants or other additives, particle size of the active ingredients, etc.

Accordingly, preferred formulations for administering soluble antigens and CTL-stimulatory cytokines within the methods of the invention are designed to optimize mucosal delivery. These agents may thus include clycdextrins and beta-cyclodextrin derivatives (eg., 2-hydroxypropyl-beta-cyclodextrin and heptakis(2,6-di-O-methyl-beta-cyclodextrin). These compounds, preferably conjugated with one or more of the active ingredients and formulated in an oleaginous base, are well documented to enhance bioavailability in intrarectal formulations. Other absorption-enhancing agents adapted for intrarectal delivery include medium-chain fatty acids, including mono- and diglycerides (eg., sodium caprate--extracts of coconut oil, Capmul), and triglycerides (eg., amyloextrin, Estaram 299, Miglyol 810).

It is well known in the medical arts that dosages for any one human subject depend on many factors, as well as the particular compound to be administered, the time and route of administration and other drugs being administered concurrently. Dosages for the soluble antigens of the invention will vary, but can be approximately 0.01 mg to 100 mg per administration. Dosages for the mucosal adjuvants will be approximately 0.001 mg to 100 mg per administration. Dosages for IL-12 will be approximately 25  $\mu$ g/kg to 500  $\mu$ g/kg and for IFN $\gamma$  will be 300 KU to 30,000 KU per administration--comparable dosages will be used for other cytokines. For example, 3,000 KU of IFN $\gamma$  can be administered to a human patient once per week. Methods of determining optimal doses are well known to pharmacologists and physicians of ordinary skill. Routes will be, as recited *supra*, mucosal, e.g., IR, IG, IVG, IN, IPG or IT.

*B.2.2 Administration of soluble antigens utilizing expression vectors encoding the soluble antigens.*

An expression vector is composed of or contains a nucleic acid in which a polynucleotide sequence encoding a peptide or polypeptide of the invention is operatively linked to a promoter or enhancer-promoter combination. A promoter is a transcriptional regulatory element composed of a region of a DNA molecule typically within 100 nucleotide pairs upstream of the point at which transcription starts. Another transcriptional regulatory element is an enhancer. An enhancer provides specificity in terms of time, location and expression level. Unlike a promoter, an enhancer can function when located at variable distances from the transcription site, provided a promoter is present. An enhancer can also be located downstream of the transcription initiation site. A coding sequence of an expression vector is operatively linked to a transcription terminating region. To bring a coding sequence under control of a promoter, it is necessary to position the translation initiation site of the translational reading frame of the peptide or polypeptide between one and about fifty nucleotides downstream (3') of the promoter. Examples of particular promoters are provided *infra*. Expression vectors and methods for their construction are known to those familiar with the art.

— Suitable vectors include plasmids, and viral vectors such as herpes viruses, retroviruses, vaccinia viruses, attenuated vaccinia viruses, canary pox viruses, adenoviruses and adeno-associated viruses, among others.

The application of antigen-encoding genes to the mucosal induction of CTL in humans can utilize either *in vivo* or *ex vivo* based approaches.

The *ex vivo* method includes the steps of harvesting cells (e.g., dendritic cells) from a subject, culturing the cells, transducing them with an expression vector, and maintaining the cells under conditions suitable for expression of the soluble antigen. These methods are well known in the art of molecular biology. The transduction step is accomplished by any standard means used for *ex vivo* gene

therapy, including calcium phosphate, lipofection, electroporation, viral infection, and biolistic gene transfer. Cells that have been successfully transduced are then selected, for example, for expression of a drug resistance gene. The cells can then be lethally irradiated (if desired) and injected or implanted into the subject. IL-12 and IFN $\gamma$  can be administered either systemically or to the relevant mucosal surface as discussed above (Section B.2.1).

The *in vivo* approach requires delivery of a genetic construct directly into the mucosa of a subject, preferably targeting it to the cells or tissue of interest (e.g., dendritic cells in PP). This can be achieved by administering it directly to the relevant mucosa (e.g., IR in the case of PP). Tissue specific targeting can also be achieved by the use of a molecular conjugate composed of a plasmid or other vector attached to poly-L-lysine by electrostatic or covalent forces. Poly-L-lysine binds to a ligand that can bind to a receptor on target cells (Cristiano et al. J. Mol. Med 73:479 (1995)). Similarly, cell specific antibodies of the type described *supra* in Section B.2.1 can be bound to vectors and thereby target them to the relevant cells of the mucosal immune system. A promoter inducing relatively tissue or cell-specific expression can be used to achieve a further level of targeting. Appropriate tissue-specific promoters include, for example, the inducible IL-2 (Thompson et al., Mol. Cell. Biol. 12: 1043 (1992)), IL-4 (Todd et al., J. Exp. Med. 177:1663 (1993)) and IFN $\gamma$  (Penix et al., J. Exp. Med. 178:483 (1993)) T-cell targeting promoters. These promoters would allow production of the soluble antigens in lymphoid tissue, including mucosal lymphoid tissue, e.g., PP. Naturally, an ideal promoter would be a dendritic cell specific promoter.

Vectors can also be delivered by incorporation into liposomes or other delivery vehicles either alone or co-incorporated with cell specific antibodies, as described *supra* in Section B.2.1.

DNA or transfected cells can be administered in a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are biologically compatible vehicles which

are suitable for administration to a human, e.g., physiological saline. A therapeutically effective amount is an amount of the DNA of the invention which is capable of producing a medically desirable result in a treated animal.

5 As is well known in the medical arts, the dosage for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.

10 Dosages will vary, but a preferred dosage for administration of DNA is from approximately  $10^6$  to  $10^{12}$  copies of the DNA molecule. This dose can be repeatedly administered, as needed. Routes of administration will be the mucosal routes recited for soluble antigens *supra* in Section B.2.1. The  
15 mucosal adjuvants, IL-12 and IFN $\gamma$  can also be administered in the same combinations, by the same routes and at the same dosages recited in Section B.2.1.

### B.3 Sources of peptides and polypeptides

20 Peptides and polypeptides used in the methods of the invention can be obtained by a variety of means. Smaller peptides (less than 100 amino acids long) can be conveniently synthesized by standard chemical methods familiar to those skilled in the art (e.g., see Creighton, *Proteins: Structures and Molecular Principles*, W.H. Freeman and Co., N.Y. (1983)).  
25 Larger peptides (longer than 100 amino acids) can be produced by a number of methods including recombinant DNA technology (see *infra*). Some polypeptides (e.g., HIV-1, gp160, CT, LT, IL-12, or IFN $\gamma$ ) can be purchased from commercial sources.

30 Polypeptides such as HIV-1, gp160, CT, IL-12, or IFN $\gamma$  can be purified from biological sources by methods well-known to those skilled in the art (*Protein Purification, Principles and Practice*, second edition (1987) Scopes, Springer Verlag, N.Y.). They can also be produced in their  
35 naturally occurring, truncated, chimeric (as in the CLUVAC, for example), or fusion protein forms by recombinant DNA technology using techniques well known in the art. These methods include, for example, *in vitro* recombinant DNA

techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, N.Y.,; and Ausubel et al., eds. (1989), *Current Protocols in Molecular Biology*, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., N.Y.. Alternatively, RNA encoding the proteins can be chemically synthesized. See, for example, the techniques described in *Oligonucleotide Synthesis*, (1984) Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

A variety of host-expression vector systems can be utilized to express the nucleotide sequences. Where the peptide or polypeptide is soluble, it can be recovered from: (a) the culture, i.e., from the host cell in cases where the peptide or polypeptide is not secreted; or (b) from the culture medium in cases where the peptide or polypeptide is secreted by the cells. The expression systems also encompass engineered host cells that express the polypeptide *in situ*, i.e., anchored in the cell membrane. Purification or enrichment of the polypeptide from such an expression system can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. Alternatively, such engineered host cells themselves can be used in situations where it is important not only to retain the structural and functional characteristics of the protein, but also to assess biological activity.

The expression systems that can be used for purposes of the invention include but are not limited to microorganisms such as bacteria (for example, *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the nucleotide sequences; yeast transformed with recombinant yeast expression vectors; insect cells infected with recombinant viral expression vectors (baculovirus); plant cell systems infected with recombinant viral expression vectors (e.g., cauliflower mosaic virus, CAMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors; or



mammalian cells (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses.

5           In bacterial systems, a number of expression vectors can be advantageously selected depending upon the use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, e.g., for *in vivo* immunization, vectors which direct the  
10           expression of high levels of fusion protein products that are readily purified can be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278, (Ruther et al., EMBO J. 2:1791 (1983)), in which the coding sequence can be ligated individually into the vector in frame  
15           with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101 (1985); Van Heeke & Schuster, J. Biol. Chem. 264:5503 (1989)); and the like. pGEX vectors can also be used to  
20           express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by  
25           elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

          In mammalian host cells, a number of viral-based expression systems can be utilized. In cases where an  
30           adenovirus is used as an expression vector, the nucleotide sequence of interest can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted in the adenovirus genome by *in vitro* or  
35           *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the gene product in infected hosts (e.g., See Logan and Shenk, Proc. Natl. Acad. Sci. USA 81:3655 (1984)). Specific

initiation signals can also be required for efficient translation of inserted nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (Bittner et al., Methods in Enzymol. 153:516 (1987)).

In addition, a host cell strain can be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, and WI38.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells can be allowed to grow for 1-2 days in

an enriched medium, and then are switched to a selective medium. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express the gene product. Such engineered cell lines can be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product.

A fusion protein can be readily purified by utilizing an antibody or a ligand that specifically binds to the fusion protein being expressed. For example, a system described by Janknecht et al., Proc. Natl. Acad. Sci. USA 88:8972 (1991) allows for the ready purification of non-denatured fusion proteins expressed in human cell lines. In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni<sub>2</sub>+ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers. If desired, the histidine tag can be selectively cleaved with an appropriate enzyme.

The following examples are meant to illustrate the invention and not to limit it.

#### EXAMPLES

##### Materials and Methods

Human IR immunization Soluble antigens of the invention are dissolved in a pharmaceutically acceptable carrier, e.g., physiological saline and administered with and without adjuvant and with or without cytokines, e.g., IL-12 and/or IFN $\gamma$ . The latter can be administered systemically or together with the antigen. Dosages of soluble antigen are approximately 0.001 mg to 100 mg per administration. Administration can be single, or multiple. In the case of

multiple immunizations, there can, for example, be four weekly administrations, followed (if desired) by a booster administration several months (e.g., two, three, four, six, eight or twelve) or several years (e.g., two, three, four, five, ten, twenty or thirty) thereafter. Administration of the antigen (with and without adjuvant and with and without cytokine) can be by IR insertion of a suppository into which the immunizing composition has been incorporated, by enema or by flexible sigmoidoscope.

CTL activation cultures At various time points after immunization (different for each experiment), CTL activity was assessed. BALB/c mice were sacrificed and the intestines and SP were surgically removed. Single cell suspensions were prepared from the organs by methods familiar to those of average skill in the art. In the case of PP and LP, the PP were first dissected from the outer surface of the intestine. The rest of the intestine was cut into small fragments 1 to 3 mm square which were suspended in phosphate buffered saline (PBS). The tissue fragment suspension was stirred for 20 minutes at room temperature and shaken under the same conditions to liberate the intraepithelial lymphocytes (IEL) from the tissue. The suspended IEL were discarded and tissue fragments were treated with collagenase type VIII (Sigma) (300U/ml) dissolved in PBS for 1 hour at room temperature to release the LP cells. PP cells were extracted from the dissected PP by the same collagenase treatment. Cells (PP or LP) were then placed on a discontinuous gradient containing 75% and 40% of Percoll, followed by centrifugation at 2,000 r.p.m. for 20 minutes. Lymphocytes were harvested from the 75%/40% interface and washed two times. Immune cells from SP, PP, LP were cultured with  $1\mu\text{M}$  P18IIIB-I10 peptide at  $5 \times 10^6$  per/milliliter in 24-well culture plates in complete T cell medium (CTM): RPMI 1640 containing 10% fetal bovine serum, 2mM L-glutamine, penicillin (100U/ml), streptomycin (100 $\mu\text{g}$ /ml), and  $5 \times 10^{-5}$  M 2-mercaptoethanol. P18IIIB-I10 is a peptide containing the minimal essential CTL epitope of P18IIIB (SEQ ID NO:15) and has the sequence: RGPGRAFVTI (SEQ ID NO:16).

Three days later, 10% supernatant from concanavalin A activated spleen cells was added as a source of interleukin-2 (IL-2). After 7 days of culture, LP lymphocytes (LPL) were stimulated in a second 7 day culture with 1 $\mu$ M P18IIIB-I10 peptide (SEQ ID NO:16) together with 4 X 10<sup>6</sup> of 3300-rad irradiated syngeneic SP cells. Immune SP and PP cells were similarly stimulated in vitro for two 7-day culture periods before assay. Cytolytic activity of CTL was measured by a 4-hour assay with <sup>51</sup>Cr labeled P815 targets using a method familiar to those of ordinary skill in the art. For testing the peptide specificity of CTL, <sup>51</sup>Cr-labeled P815 targets were pulsed for 2 hours with peptide at the beginning of the assay. The percent specific <sup>51</sup>Cr release was calculated as 100X (experimental release-spontaneous release)/(maximum release-spontaneous release). Maximum release was determined from supernatants of cells that were lysed by addition of 5% Triton-X 100. As a control, spontaneous release was determined from target cells incubated without added effector cells. Standard errors of the mean of triplicate cultures were all <5% of the mean.

Viral plaque assay Six days after IR challenge with recombinant vaccinia virus expressing HIV-1 IIIB gp160 (vPE16), mice were sacrificed. Their ovaries were removed, dissociated into single cell suspensions and assayed for vPE16 titer by plating serial 10-fold dilutions on a plate of BSC-2 indicator cells, staining with crystal violet and counting plaques at each dilution. The minimal detectable level of virus was 70 plaque forming units (pfu).

**Example 1. Comparison of mucosal and systemic CTL responses after mucosal and systemic immunization**

Mice were immunized IR with 4 doses (on days 0, 7, 14 and 21) of the HIV-1 CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50 $\mu$ g/mouse). 5 weeks to 6 months after the first dose, antigen-specific T cells were isolated from PP, LP and SP and tested for the presence of HIV-1 P18IIIB peptide specific CTL (Fig. 1), as described above. Closed squares show killing of

P18IIIB-I10 (SEQ ID NO:16) -pulsed targets and open diamonds show killing on unpulsed targets. IR immunization induced long-lasting protective immune responses: antigen-specific CTL were detected in mucosal inductive (PP) and effector (LP) sites and in a systemic site (SP) at least 6 months after immunization. In contrast, systemic immunization (s.c. in incomplete Freund's adjuvant) induced CTL in the spleen but not in the mucosal immune system (i.e., PP and LP).

**Example 2. Comparison of CTL responses with and without a mucosal adjuvant**

BALB/c mice were immunized IR with 4 doses of the synthetic HIV-1 CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50µg/mouse per immunization) alone, i.e., in the absence of adjuvant or cytokine on days 0, 7, 14 and 21. In parallel, another group of mice was immunized IR with PCLUS3-P18IIIB (SEQ ID NO:2) HIV-1 peptide in combination with CT (1µg/mouse). On day 35 antigen-specific T cells were isolated from PP, LP and SP. Immune cells from SP, PP, or LP were cultured and tested for antigen specific CTL (Fig. 2), as described above. Closed squares show killing of P18IIIB-I10 (SEQ ID NO:16) pulsed targets, and open diamonds show killing of unpulsed targets. IR administration of peptide alone induced a significant response. The response was enhanced by the co-administration of CT.

**Example 3. CTL induced by mucosal immunization lyse targets expressing HIV-1 gp160 envelope protein**

Mice were immunized IR with 4 doses (on days 0, 7, 14 and 21) of the HIV-1 CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (5µg/mouse per immunization) in the presence of CT (1µg/mouse). on day 35, antigen-specific T cells were isolated from PP, LP and SP. Immune cells from SP, PP, or LP were cultured as described above. Cytolytic activity of CTL was measured using a standard <sup>51</sup>Cr release assay (Fig. 3).

Three different cell lines were used as target cells: 15-12 cells, 3T3 18 Neo BALB/c cells and P815 cells.

15-12 cells are BALB/c 3T3 fibroblasts transfected with a vector encoding HIV-1 gp160 (Takahashi et al. Proc. Natl. Acad. Sci. USA 85:3105 (1988)); 3T3 18 Neo BALB/c cells are BALB/c 3T3 fibroblasts transfected with an expression vector containing a Neor gene but no gp160 gene; and P815 cells are untransfected cells that present antigenic peptides added to the culture. CTL lysis of gp160 expressing 15-12 cells (closed squares in right panels) was compared to that of control gp160 non-expressing 3T3 18 Neo BALB/c cells (open diamonds right panels). P815 target cells (left panel) were tested in the presence (closed squares) or absence (open diamonds) of P18IIIB-I10 peptide (SEQ ID NO:16) (1 $\mu$ M). The percent specific <sup>51</sup>Cr release was calculated as described above. CTL induced by IR immunization killed target cells either endogenously expressing HIV-gp160 or pulsed with P18IIIB peptide (SEQ ID NO:15).

**Example 4. CTL induced by IR immunization  
are IL-12 dependent.**

BALB/c mice were immunized IR with 4 doses (on days 0, 7, 14 and 21) of CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50 $\mu$ g/mouse per immunization) in combination with CT (1 $\mu$ g/mouse). One day before and one day after immunization with peptide mice were treated intraperitoneally (i.p.) with anti-IL-12 antibody (0.5 mg/per injection: 4mg/mouse total dose (Fig. 4, right panels) or were untreated (Fig. 4, left panels). On day 35, antigen-specific T cells were isolated from PP, LP and SP. Immune cells from SP, PP, or LP were cultured as described above. Cytolytic activity of CTL was measured (Fig. 4) as described above. For testing the peptide specificity of CTL, <sup>51</sup>Cr labeled P815 targets were pulsed with peptide P18IIIB-I10 (SEQ ID NO:16) at the beginning of the assay (closed squares), or (as a control) left unpulsed i.e., without peptide (open diamonds). Induction of both mucosal and systemic CTL responses by IR immunization was IL-12-dependent, as shown by inhibition of induction of CTL in mice treated i.p. with anti-IL-12 antibody.

BALB/c mice were immunized IR on days 0, 7, 14 and 21 with either composition A containing the synthetic *HIV-1* CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50µg/mouse per immunization), CT (10µg/mouse per immunization), and recombinant IL-12 (1µg/mouse per immunization), or composition B containing the synthetic *HIV-1* CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50µg/mouse per immunization), and CT (10µg/mouse per immunization), on day 35, antigen-specific T cells were isolated from PP and SP. Immune cells from PP (Fig. 9A) and SP (Fig. 9B) were separately cultured and tested for antigen specific CTL, as described above. Fig. 9A shows killing of peptide P18IIIB-I10 (SEQ ID NO:16) pulsed target cells by effector cells from mice immunized with composition A (i.e., antigen with IL-12) (open squares), and Fig. 9B shows killing of the P18IIIB-I10 (SEQ ID NO:16) pulsed target cells by effector cells from mice immunized with composition B (i.e., antigen without IL-12) (open diamonds). In both Figs. 9A and 9B, control data was obtained using the two effector populations tested on unpulsed targets. The enhanced CTL responses of both PP (Fig. 9A) and SP (Fig. 9B) effector cells from mice immunized IR with composition A compared to the responses elicited by IR immunization with composition B indicate that co-administration of IL-12 augments mucosal and systemic CTL responses. These data both provide independent evidence for the role of IL-12 in eliciting mucosal (and systemic) immunity by mucosal administration of antigens and confirm the findings of the antibody inhibition data described above.

**Example 5. Intrarectal peptide immunization protects against mucosal challenge with HIV-gp160 expressing recombinant vaccinia virus.**

Groups of 5 mice were immunized IR with 4 doses of the *HIV-1* CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50µg/mouse per immunization) on days 0, 7, 14 and 21 in combination with CT. On day 35, mice were challenged IR with  $2.5 \times 10^7$  pfU of vaccinia virus expressing gp160IIIB (vPE16). After 6 days, the mice were killed and their ovaries assayed for the



presence of virus (Fig. 5) as described above. The left bar of Fig. 5 shows virus titer in the ovaries of unimmunized mice and the right bar shows virus titer in the ovaries of immunized mice. IR immunization with PLCUS3-18IIIB (SEQ ID NO:2) protected mice against IR challenge with vPE16 as shown by a 4.5-log reduction in viral pfu in ovaries compared to unimmunized animals ( $p < 0.005$ ).

**Example 6. Comparison of systemic CTL responses six months after IR and IN immunization**

10

Mice were immunized IR or IN with 4 doses (on days 0, 7, 14 and 21) of the HIV-1 CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) ( $50\mu\text{g}/\text{mouse}$ ). Six months after the first dose, antigen-specific T cells were isolated from SP and tested for the presence of HIV-1 P18IIIB-I10 (SEQ ID NO:16) peptide specific CTL (Fig. 6A and 6B) as described above. Closed squares show killing of P18IIIB-I10 (SEQ ID NO:16)-pulsed targets and open diamonds show killing of unpulsed targets. The level of CTL activity induced by IR immunization (Fig. 6A) was higher than that induced by IN immunization (Fig. 6B). These data indicate that IR immunization induced potent, long-lasting, antigen-specific splenic immune responses.

20

To evaluate different routes of immunization, mice were immunized mucosally (IR, IN, IG) or systemically (SC) with 4 doses (on days 0, 7, 14 and 21) of the HIV-1 CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) ( $50\mu\text{g}/\text{mouse}$ ). Thirty-five days after the first dose, antigen-specific T cells were isolated from PP and SP and tested for the presence of HIV-1 P18IIIB-I10 (SEQ ID NO:16) peptide-specific CTL as described above (Fig. 7). Closed bars show killing of P18IIIR-I10 (SEQ ID NO:16) pulsed targets and open bars show killing on unpulsed targets. The level of CTL activity induced by IR immunization was significantly higher in inductive mucosal tissue (PP) and much higher in systemic immunological tissue (SP) than that induced by the other mucosal routes (IN and IG). CTL activity was detected in both PP and SP after immunization via all three mucosal routes. Systemic immunization (SC) only resulted in significant CTL activity in SP.

30

35

**Example 7. CTL induced by IR immunization  
are IFN $\gamma$  dependent.**

Wild-type BALB/c mice and BALB/c mice lacking the ability to produce functional IFN $\gamma$  (IFN $\gamma^{-/-}$  mice) (Dalton et al., Science 259:1739 (1993); Tishon et al., Virology 212:244 (1995)) were immunized IR with 4 doses (on days 0, 7, 14 and 21) of CLUVAC PCLUS3-18IIIB (SEQ ID NO:2) (50 $\mu$ g/mouse per immunization) in combination with CT (1 $\mu$ g/mouse). On day 35, antigen-specific T cells were isolated from PP, LP and SP. Immune cells from SP, PP, or LP of wild type BALB/c and IFN $\gamma^{-/-}$  mice were cultured as described above. Cytolytic activity of CTL was measured (Fig. 8A and Fig. 8B) as described above. The peptide specificity of CTL was tested as follows: <sup>51</sup>Cr labeled P815 targets were pulsed with peptide P18IIIB-I10 (SEQ ID NO:16) at the beginning of the assay (solid bars), or (as a control) left unpulsed i.e., without peptide (open bars). Induction of both mucosal and systemic CTL responses by IR immunization was IFN $\gamma$  dependent, as shown by the lack of detectable CTL activity in SP, PP, and LP cells from IFN $\gamma^{-/-}$  mice (Fig. 8B) and potent CTL activity in SP, PP, and LP cells from wild-type BALB/c mice (Fig. 8A).

Summarizing the foregoing results, mucosal, administration of an antigenic peptide to mice results in the induction of a protective CTL response detectable in both the inductive (Peyer's patch (PP)) and effector (lamina propria (LP)) sites of the intestinal mucosal immune system, as well as in systemic lymphoid tissue, i.e., spleen (SP). The mucosal CTL response is enhanced by co-administering the mucosal adjuvant, cholera toxin (CT) with the antigenic peptide, is inhibited by antibody that specifically binds to (thereby neutralizing the activity of) interleukin-12 (IL-12), and is not detectable in mice lacking the ability to produce functional interferon- $\gamma$  (IFN $\gamma$ ). Furthermore, including IL-12 in the composition of antigenic peptide and CT used for IR immunization resulted in enhanced PP and SP CTL responses relative to those obtained by IR immunization with antigenic peptide, CT and no IL-12. IR immunization with the viral

peptide resulted in protection from viral infection upon subsequent IR challenge with the appropriate virus.

**Example 8. Comparison of different HIV vaccine peptides for use in eliciting viral mucosal protection**

Because of the variability of the V3 loop of HIV, further studies were conducted comparing two cluster peptide constructs using the V3 loop and incorporating the CTL epitope P18 from strain IIIB (Ratner et al., Nature 313:277-284, (1985)) or MN (Gurgo et al., Virology 164:531-536, (1998)) of HIV-1. These studies were conducted as an exemplary analysis to demonstrate that HIV vaccine cluster peptide constructs can be prepared from different HIV strains and screened in side-by-side assays to optimize induction of mucosal CTL immunity.

Animals For each of the following Examples, female BALB/c mice were purchased from Frederick Cancer Research Center (Frederick, MD). IFN- $\gamma^{-/-}$  mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice used in this study were 6-12 weeks old. The IFN- $\gamma^{-/-}$  mice were maintained in a specific pathogen-free microisolator environment.

Immunization Mice were immunized with 4 doses of the synthetic HIV peptide vaccine construct PCLUS3-18IIIB (Ahlers et al., J. Immunol. 150:5647-5665, (1993)) (50 $\mu$ g/mouse for each immunization) on days 0, 7, 14 and 21 in combination with cholera toxin (CT) (10  $\mu$ g/mouse) (List Biological Laboratories, Campbell, CA) by intrarectal administration. For subcutaneous immunization, incomplete Freund's adjuvant was used. rm IL-12 (a generous gift of Genetics Institute, Inc., Cambridge, MA) was delivered either intraperitoneally (IP) (1 $\mu$ g) or intrarectally (1 $\mu$ g) mixed with DOTAP (Boehringer Mannheim), a cationic lipofection agent, along with the peptide vaccine.

Cell purification Five weeks to 6 months after the first dose, antigen-specific T cells were isolated from Peyer's patches (PP), lamina propria (LP) and the spleen (SP). The Peyer's patches were carefully excised from the intestinal wall and dissociated into single cells by use of collagenase type VIII, 300U/ml (Sigma) as described, Mega et al., Int.

Immunol. 3:793-805, (1991). Our data showed that most PP CD3<sup>+</sup> T cells isolated from normal mice were CD4<sup>+</sup>, while CD3<sup>+</sup>CD8<sup>+</sup> T cells were less frequent. Further, collagenase did not alter expression of CD3, CD4, or CD8 on splenic T cells treated with this enzyme. Lamina propria lymphocyte (LPL) isolation was performed as described, Mega et al., Int. Immunol. 3:793-805, (1991). The small intestines were dissected from individual mice and the mesenteric and connective tissues carefully removed. Fecal material was flushed from the lumen with unsupplemented medium (RPMI 1640). After the PP were identified and removed from the intestinal wall, the intestines were opened longitudinally, cut into short segments, and washed extensively in RPMI containing 2% fetal bovine serum (FBS). To remove the epithelial cell layer, tissues were placed into 100ml of 1 mM EDTA and incubated twice (first for 40 min and then for 20 min) at 37°C with stirring. After the EDTA treatment, tissues were washed in complete RPMI medium for 10 min at room temperature and then placed into 50 ml of RPMI containing 10% FCS and incubated for 15 min at 37° with stirring. The tissues and medium were transferred to a 50 ml tube and shaken vigorously for 15 seconds, and then the medium containing epithelial cells was removed. This mechanical removal of cells was repeated twice more, using fresh medium each time, in order to completely remove the epithelial cell layer. Histologic examination revealed that the structure of the villi and lamina propria were preserved. To isolate LPL, tissues were cut into small pieces and incubated in RPMI 1640 containing collagenase type VIII 300 U/ml (Sigma) for 50 min at 37°C with stirring. Supernatants containing cells were collected, washed and then re-suspended in complete RPMI 1640. This collagenase dissociation procedure was repeated two times and the isolated cells pooled and washed again. Cells were passed through a cotton-glass wool column to remove dead cells and tissue debris and then layered onto a discontinuous gradient containing 75% and 40% Percoll (Pharmacia Fine Chemicals, Pharmacia Inc., Sweden). After centrifugation (4°C, 600g, 20min), the interface layer between the 75% and 40% Percoll was carefully removed and washed with incomplete

medium. This procedure provided >90% viable lymphocytes with a cell yield of  $1.5-2 \times 10^6$  lymphocytes/mouse. The SP were aseptically removed and single cell suspensions prepared by gently teasing them through sterile screens. The erythrocytes were lysed in Tris-buffered ammonium chloride and the remaining cells washed extensively in RPMI 1640 containing 20% FBS.

Cytotoxic T lymphocyte assay Immune cells from SP, PP, LP were cultured at  $5 \times 10^6$  per/milliliter in 24-well culture plates in complete T cell medium (CTM): RPMI 1640 containing 10% FBS, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100  $\mu$ g/ml), and  $5 \times 10^{-5}$  M 2-mercaptoethanol. Three days later we added 10% concanavalin A supernatant-containing medium as a source of IL-2. LPL were studied after 7 days stimulation with  $1 \mu$ M P18IIIB-I10 peptide together with  $4 \times 10^6$  of 3300-rad irradiated syngeneic spleen cells. SP and PP cells were stimulated in vitro similarly for one or two 7-day culture periods before assay. Cytolytic activity of CTL lines was measured by a 4-hour assay with  $^{51}\text{Cr}$  labeled targets. Two different cell lines were used as a target cells: 1) 15-12 cells, Takahashi et al., Proc. Natl. Acad. Sci. USA 85:3105-3109 (1988) (BALB/c 3T3 fibroblasts transfected with HIV-1IIIB gp160 and endogenously expressing HIV gp160), compared with 18 Neo BALB/c 3T3 fibroblasts transfected with Neo<sup>R</sup> alone as a control, and 2) P815 targets tested in the presence or absence of I10 peptide ( $1 \mu$ M). For testing the peptide specificity of CTL,  $^{51}\text{Cr}$  labeled P815 targets were pulsed for 2 hours with peptide at the beginning of the assay. The percent specific  $^{51}\text{Cr}$  release was calculated as  $100 \times (\text{experimental release} - \text{spontaneous release}) / (\text{Maximum release} - \text{spontaneous release})$ . Maximum release was determined from supernatants of cells that were lysed by addition of 5% Triton-X 100. Spontaneous release was determined from target cells incubated without added effector cells.

Vaccinia virus Recombinant vaccinia virus vPE16 expresses the HIV-1 gp160 gene from isolate IIIB (BH8) (Earl et al., J. Virol. 64:2448-2451 (1990)). Expression is directed by the compound early/late P7.5 promoter. Two copies

of the sequence T5NT, which serves as a transcription termination signal for early vaccinia virus genes, are present in the IIIB gp 160 gene. Both of these have been altered in vPE16, so as to retain the original coding sequence and allow early transcription of the gene. The virus, vSC8, is used as a negative control without gp160 (Chakrabarti et al., Mol. Cell Biol. 5:3403-3409 (1985)). Both vPE16 and VSC8 express beta-galactosidase.

Determination of virus titer in the ovary On day 35 or 6 months after cluster peptide HIV vaccine immunization, mice were challenged intrarectally with  $2.5 \times 10^7$  or  $5 \times 10^7$  pfu of vaccinia virus expressing gp160IIIB (vPE16). Six days after the challenge with recombinant vaccinia virus expressing HIV-gp160, the mice were killed and ovaries were removed, homogenized, sonicated, and assayed for vPE16 titer by plating serial 10-fold dilutions on a plate of BSC-2 indicator cells staining with crystal violet and counting plaques at each dilution. The minimal detectable level of virus was 100 pfu.

To compare different HIV vaccine cluster peptide constructs, BALB/c mice were immunized intrarectally with peptide (PCLUS3-18IIIB or PCLUS3-18MN) in the presence of CT as a mucosal adjuvant weekly for four weeks (on days 0, 7, 14, and 21). Mice were studied either two weeks later (day 35) or at six months for memory CTL responses in the Peyer's Patches (PP) or spleen (SP). IR immunization with both peptides PCLUS3-18IIIB or PCLUS3-18MN in combination with CT induces a P18-specific CTL response in the intestinal PP (Fig. 10, panel A) and in the spleen (Fig. 10, panel B).

However, the level of CTL response after IR immunization with PCLUS3-18MN was significantly lower than after IR immunization with PCLUS3-18IIIB. The difference may reflect a higher affinity of the minimal 10-mer P18IIIB-I10, compared to P18MN-T10, for H-2D<sup>d</sup> (Takahashi et al., Science 246:118-121 (1989); Takeshita et al., J. Immunol. 154:1973-1986 (1995)). Also, much higher production of IFN- $\gamma$  by mucosal P18IIIB-specific CD8<sup>+</sup> CTL was observed compared to P18-MN-specific CTL after stimulation with specific peptide in vitro for 48 hours. When tested on 15-12 gp160IIIB-

transfected fibroblast targets endogenously expressing gp 160IIIB, the CTL elicited by immunization with PCLUS3-18IIIB also killed these targets. On the basis of these observations, the PCLUS3-18IIIB construct was used in the protection experiments described below.

**Example 9. Mucosal immunization of mice with cluster peptide construct provides longlasting protection from infection with recombinant vaccinia virus expressing HIVg160**

In the foregoing Examples, the ability of the mucosal immune responses induced by the HIV cluster peptide vaccine to protect against virus challenge via a mucosal route is demonstrated. To determine the specificity of this protection for recombinant protein HIV-1 IIIB gp160, IR immunized mice were challenged on day 35 after the start of immunization by IR infusion with vaccinia virus expressing HIV-1 IIIB gp 160 (vPE16), or with control vaccinia virus expressing  $\beta$ -galactosidase (vSC8). Unimmunized animals challenged with vPE16 or vSC8 served as controls. Six days after the challenge, mice were sacrificed and the ovaries were removed and assayed for vaccinia titer (6 days after infection with vaccinia, the ovaries contain the highest titer of virus).

IR immunization with the synthetic HIV peptide vaccine protected mice against an IR challenge with vaccinia virus expressing HIV-1 IIIB gp160 compared to unimmunized controls, but did not protect against IR challenge with vaccinia virus expressing only an unrelated protein,  $\beta$ -galactosidase (Fig. 11). Thus, the protection was specific for virus expressing HIV-1 gp160, and any nonspecific inflammatory response induced by the peptide infusion intrarectally was not sufficient to protect against viral challenge two weeks after the last dose of the immunization.

Although the presence of mucosal memory CTL precursors was observed, requiring restimulation *in vitro* for activity 6 months after IR immunization (Belyakov et al., Proc. Natl. Acad. Sci. 95:1709-1714 (1998)), the strength and duration of protection remained unclear. To resolve this

question, the IR immunized mice were challenged 6 months after the start of immunization with PCLUS3-18IIIB by IR administration with vaccinia virus expressing HIV-1 IIIB (vPE16). This study showed that, even 6 months after HIV cluster peptide immunization, BALB/c mice exhibit protection against recombinant HIV-vaccinia challenge (Fig. 12).

**Example 10. Protection of mice against mucosal viral challenge is mediated by CD8<sup>+</sup> CTL in the mucosal site**

To determine the immune mechanism responsible for protection against mucosal challenge with virus expressing HIV gp160, mice were treated IP with 0.5 mg monoclonal anti-CD8 antibody (clone 2.43, NIH, Frederick, MD) one day before and after each of the four immunizations and also two days before and three days after the challenge with vPE16. This treatment led to a significant inhibition of the protection against mucosal challenge with vPE16 (Fig. 13). Thus, protection in the mucosal site against the virus expressing HIV-1 gp160 is mediated by CD8<sup>+</sup> lymphocytes.

Because the HIV peptide constructs disclosed herein elicit both strong mucosal and systemic MHC class I restricted CD8<sup>+</sup> CTL responses (Belyakov et al., Proc. Natl. Acad. Sci. 95:1709-1714 (1998)), the role of these responses in mediating protection were further investigated. Because SC immunization with peptide vaccine elicits splenic but not mucosal CTL, whereas IR immunization elicits both (Fig. 14), SC and IR immunizations can be compared to determine whether systemic CTL are sufficient to protect against mucosal challenge, or whether local mucosal CTL are necessary. Accordingly, mice were immunized with PCLUS3-18IIIB plus IFA by the SC route or with PCLUS3-18IIIB and CT by the IR route on days 0, 7, 14 and 21, and compared these. On day 35 after the start of immunization, these groups of mice as well as unimmunized control mice were challenged by IR administration of vaccinia virus expressing HIV-1 gp160 (vPE16). Finally, six days after the challenge, mice were sacrificed and their ovaries assayed for viral titer.



SC immunization with PCLUS3-18IIIB did not protect mice against mucosal challenge with vPE16, whereas IR immunization with the same peptide did protect (Fig. 14B). Thus, protection against mucosal challenge with virus expressing HIV-1 gp160 can be induced only by mucosal immunization of mice, and correlates with local mucosal CTL activity, not with splenic CTL activity. On this basis one can conclude that the CD8<sup>+</sup> CTL-mediated protection from mucosal challenge with recombinant vaccinia expressing HIV-1 gp160 requires local mucosal CD8<sup>+</sup> CTL, whereas a systemic CTL response is not sufficient.

**Example 11. Cytokine dependence and enhancement of protection by local administration of IL-12 with the vaccine**

Induction of mucosal CTL by peptide vaccine is dependent on endogenous IL-12 in that it can be blocked by *in vivo* treatment of mice with anti-IL-12 (Belyakov et al., Proc. Nati. Acad. Sci. 95:1709-1714, (1998)). To further define the role of IL-12 in the CTL response and protection, BALB/c (H-2D<sup>d</sup>) mice were treated by the IP route with 1 µg of the rmIL-12 each day of the IR immunization with PCLUS3-18IIIB (50 µg/mice). This treatment did not lead to significant changes in the HIV-specific CTL activity in either mucosal or systemic sites (Fig. 15). However, when the mice were treated with the rmIL-12 (1 µg) + DOTAP intrarectally together with peptide, we found a significant increase in the CTL level in both mucosal and systemic sites 35 days after the start of immunization (Fig. 15).

In view of the above results, the possibility that rmIL-12 administered at the local site and time of mucosal immunization might increase protection against mucosal challenge with vaccinia virus expressing HIV-1 gp160 was investigated. To address this question, BALB/c mice were immunized with the rmIL-12 + DOTAP intrarectally together with peptide. The mice were then challenged mice on day 35 after the start of immunization by IR administration of vaccinia virus expressing HIV-1IIIB gp160. In this study, twice the dose of challenge virus was used, whereby the unimmunized mice

had a titer of several times  $10^{10}$  rather than several times  $10^8$  seen in the previous Examples using a lower challenge dose. Nevertheless, the immunized mice showed a reduction of greater than 4 logs in virus titer, as had been seen in the earlier experiments (Fig. 16, bar 2).

Importantly, IR immunization with the synthetic HIV peptide vaccine plus rmIL-12 protected mice against an IR challenge with this gp-160-recombinant vaccinia virus even more effectively than after the IR immunization with peptide alone (6-log reduction in viral pfu versus 4-log reduction,  $p < 0.05$ ) (Fig. 16, bar 3 versus bar 2).

As the induction of mucosal CD8<sup>+</sup> CTL is strongly dependent on IL-12 and IFN- $\gamma$  (Belyakov et al., Proc. Natl. Acad. Sci. 95:1709-1714 (1998)), further studies were undertaken herein to determine which cytokine acts directly for the generation of mucosal CTL, and which acts through a secondary mechanism. To address this question, IFN $\gamma$ <sup>-/-</sup> mice (BALB/c background) and conventional BALB/c mice were treated with the rmIL-12 (1  $\mu$ g/mouse) + DOTAP IR together with peptide. Mucosal treatment of IR-immunized IFN $\gamma$ <sup>-/-</sup> mice with rmIL-12 did not lead to the induction of mucosal or systemic CTL (Fig. 17). It thus appears that IL-12 cannot act directly in the induction of mucosal CD8<sup>+</sup> CTL in the absence of IFN $\gamma$ .

In summary, the foregoing Examples incorporate a novel viral challenge system in which recombinant vaccinia virus expressing HIV-1 gp160 is used as a surrogate for HIV-1, since we cannot infect the mice with HIV-1. Importantly, in this system, neutralizing antibodies to gp160 cannot protect against recombinant vaccinia expressing gp160, because the virus does not incorporate gp160 in the virus particle but expresses it only in the infected cell. Thus, the protective immune response must be directed at the infected cell.

The results herein demonstrate that the protective response is completely dependent on CD8<sup>+</sup> cells., by the abrogation of protection after *in vivo* depletion of CD8<sup>+</sup> cells. Thus, the results show unequivocally that it is CD8<sup>+</sup> CTL (whether via lytic activity or via secretion of cytokines or other soluble factors) that protect. Since it has been

shown that protection against vaccinia infection can be mediated by interferon- $\gamma$  which is secreted by CD8<sup>+</sup> CTL in response to antigen stimulation (Harris et al., J. Virol. 69:910-915 (1995)), it is possible that the mechanism involves local secretion of this cytokine by the CTL rather than lysis of infected cell. By either mechanism, the CTL are responsible for mediating protection.

However, since the mucosal immunization induces CTL in both the local mucosal site and the spleen, this result does not distinguish which CTL are responsible for protection. To address this important question, the present Examples take advantage of the fact that subcutaneous immunization with the peptide vaccine induces systemic CTL in the spleen at a level at least as high as that induced by mucosal immunization, but does not induce mucosal CTL. Splenic CTL resulting from both immunization routes kill target cells endogenously expressing HIV-1 gp160. Thus, if systemic CTL against this epitope protected against mucosal challenge, then the subcutaneously immunized mice would have been expected to be protected.

However, the subcutaneously immunized mice showed no evidence of protection against mucosal challenge. Thus, the protection correlated with CTL activity in the local mucosal sites, Peyer's patches and lamina propria, not with CTL activity in the spleen. The protection was not only mediated by CTL, but also required CTL in the local mucosal site of challenge. Systemic CTL were not sufficient.

Protection mediated by local mucosal CTL appears independently sufficient to mediate a protective immune response. This conclusion is supported by the observation that a two-log reduction in viral pfu occurs in the ovary even at day 2 after mucosal viral challenge (from  $2.37 \times 10^6$  pfu in unimmunized mice to  $3.34 \times 10^4$  pfu in IR immunized mice), before much replication could have occurred in the ovary. This finding indicates that the reduction in titer in the ovary reflects a reduction in the amount of virus that can escape the initial mucosal site of infection. In addition, the enhancement of CTL activity and protection by rmIL-12

depended on local mucosal administration of the cytokine, not systemic administration.

One possible difference between CTL induced by mucosal versus systemic immunization is that the CTL resulting from the SC immunization do not have homing receptors for the GI mucosa, as evidenced by the fact that they are not detected in the lamina propria or Peyer's patches.

The present disclosure represents the first demonstration of protection against GI mucosal challenge requiring local mucosal CTL at the site of challenge. These results have important implications for the development of protective vaccines against mucosal exposure to viruses.

In addition to these results, the Examples provided herein also demonstrate a surprising persistence, not only of memory CTL in the mucosa, but also of protective immunity against mucosal viral challenge. Factors controlling CTL memory, and the role of persistent antigen in maintaining memory CTL, represent another issue that has been of interest for some time (Ahmed and Gray, Science 272:54-60 (1996); Kundig et al., Proc. Natl. Acad. Sci. U.S.A. 93:9716-9723 (1996); Ehl et al., Eur. J. Immunol. 27:3404-3413 (1997)), but has been little studied in the context of mucosal immune responses and protection. In studies of systemic immunity, it was shown (Slifka et al., Blood 90:2103-2108, (1997)) that after infection with lymphocytic choriomeningitis virus (LCMV), CTL memory responses were present in the bone marrow for at least 325 days, indicating long-term persistence of antiviral T cells at this site. While the antigen-specific CD8<sup>+</sup> T cell number dropped precipitously following viral clearance, substantial numbers persisted for the life of the mouse (Muraii-Krishna et al., Immunity 8:177-187, (1998)). Upon rechallenge with LCMV, there was rapid expansion of memory CD8<sup>+</sup> T cells.

These results indicate that systemic infection with virus can lead to long-term memory and protection. In the case of mucosal CTL memory, it was shown that memory CTL remained at the mucosal site longer if the immunization was via the mucosal route (Gallichan and Rosenthal, J. Exp. Med.

184:1879-1890 (1996)), but the duration of protection by such mucosal CTL was not studied. The ability of mucosal memory CTL to protect will depend in part on the rapidity by which they can expand and be activated after virus exposure, which may relate to the level of virus replication in the mucosal site. For these reasons, it is important to determine the duration of mucosal protection dependent on local mucosal CD8<sup>+</sup> CTL. The results herein show persistence of CTL even six months after mucosal immunization with the peptide vaccine construct, without additional reimmunization beyond the initial three-week course. This response is accompanied by protection against mucosal challenge with vaccinia virus expressing gp160.

This latter result is particularly striking because the exemplary immunogen is a peptide administered without any depot form of adjuvant that would maintain the presence of antigen for extended periods. It would be expected that free peptide delivered to the lumen of the gut, or even after transport by mucosal cells, would have a very short half-life. Therefore, either memory CTL can persist in the mucosa at levels sufficient to mediate protection in the absence of persistent antigen, or antigen must persist locally in some cell-bound form, perhaps on N4HC molecules of dendritic cells. Yet another possibility is that the peptide crossreacts with one of the antigens in the mucosal flora and that these crossreactive antigens maintain the memory CTL.

Protection against viral infection by CTL involves more than just the number of CTL induced. Quality of CTLs is as important for *in vivo* protection as quantity. Previous reports have shown that high-avidity P18IIIB-specific CTLs adoptively transferred into severe combined immunodeficient (SCID) mice were 100- to 1000-fold more effective at viral clearance than the low-avidity CTLs specific for the same peptide-MHC complex, despite the fact that all CTL lines lysed virus infected targets *in vitro* (Alexander-Miller et al., Proc. Natl. Acad. Sci. U.S.A. 93:4102-4107 (1996)). Thus, the CTL induced by mucosal immunization with the synthetic peptide

vaccine must be present not only in sufficient quantity to protect, but also must be of high enough avidity to protect.

Other aspects of the present disclosure enable optimization of induction of the CTL response and protective immunity. Delivery of certain cytokines such as IL-12 at the site of antigen immunization systemically have been shown to enhance systemic CTL responses (Ahlers et al., J. Immunol. 159:3947-3958 (1997); Iwasaki et al., J. Immunol. 159:4591-4601 (1997); Xiang and Ertl, Immunity 2:129-135 (1995); Irvine et al., J. Immunol. 156:238-245 (1996)). However, no comparable studies have been conducted for mucosal CTL responses.

In the model system disclosed herein, induction of mucosal CTL is dependent on endogenous production of IL-12 by the mouse, because it could be inhibited by anti-IL-12 antibody given *in vivo* before and after each immunization. In the present Examples, IL-12 co-administered with the antigen intrarectally significantly enhanced CTL induction, and also increased protection against intrarectal vaccinia viral challenge. However, it was striking that IL-12 delivered systemically (*i.p.*) did not enhance CTL induction either in the systemic sites (eg. spleen) or in the mucosa. This difference may be due to the short half life of IL-12 delivered systemically, which prevented it from surviving long enough to get to the sites of CTL induction. Therefore, for mucosal CTL induction as well as for systemic CTL induction, it is important to deliver the cytokine directly to the site of antigen administration and CTL induction.

Enhancement of CTL induction in the mucosa with recombinant IL-12 is a useful strategy for mucosal vaccine development. In this context, small doses given locally in the mucosal sites are not likely to have the global toxicity that has been associated with systemic administration of this cytokine.

The results herein further show that enhancement of the CTL response *in vivo* by rmIL-12 is dependent on interferon- $\gamma$ , as no enhancement was observed in IFN $\gamma$ <sup>-/-</sup> mice. At least two mechanisms can explain this result. First, IL-12

may be acting through its well-defined ability to induce production of IFN- $\gamma$  (Trinchieri, G., Blood 94:4008-4027 (1994)), which then acts directly on CTL precursors. Alternatively, since IFN- $\gamma$  is important for expression of the IL-12 receptor (Szabo, et al., J. Exp. Med. 185:817-824 (1997)) IL-12 may act directly on CTL, but may not be able to act in IFN $\gamma$ <sup>-/-</sup> mice because of the lack of IL-12R expression.

There is evidence that CTL activity may play a role in protective immunity in humans against HIV-1 (reviewed in (Rowland-Jones et al., Adv. Immunol. 65:277-346 (1997); Yang, O. O. and B. D. Walker, Adv. Immunol. 66:273-311 (1997); Berzofsky and Berkower, AIDS 9(A):S 143-S 157 (1995)). Cell-mediated immunity to HIV-1 has been demonstrated in uninfected high risk adults (Pinto et al., J. Clin. Invest. 96:867-876, (1995); Rowland-Jones et al., Nature Medicine 1:59-64, (1995)) and in uninfected children born to infected mothers (Clerici et al., AIDS 7:1427-1433 (1993); Luzuriaga and Sullivan, J. Cell. Biochem. Supplement 17E:98.(Abstract) (1993)). CTL activity has been correlated with low viral load and long-term non-progressor status in some infected individuals (Cao et al., N. Engl. J. Med. 332:201-208 (1995)). CTL have also been associated with recovery from acute HIV or SIV infection (Yasutomi et al., J. Virol. 67:1707-1711 (1993); Reimann et al., J. Virol. 68:2362-2370 (1994); Koup et al. J. Virol. 68:4650-4655 (1994); Borrow et al., Nature Medicine 3:205-211, (1997)). Induction of escape mutations by CTL implies that the CTL are eliminating the bulk of the wild type virus (Borrow et al., Nature Medicine 3:205-211 (1997); Phillips et al., Nature 354:453-459 (1991); Nowak et al., Nature 375:606-611 (1995); Goulder et al., Nature Medicine 3:212-217 (1997); Couillin et al., J. Exp. Med. 180:1129-1134 (1994); Koenig et al., Nature Medicine 1:330-336 (1995)). In addition, in an SIV study, protection was associated with a particular simian class I MHC molecule (Heeney et al., J. Exp. Med. 180:769-774, (1994)). CD8<sup>+</sup> cells have been demonstrated to suppress replication of human and simian lentiviruses in autologous CD4 cells by a non-lytic mechanism involving soluble factors synthesized and released by activated CD8<sup>+</sup> cells (Walker et

al., Science 234:1563-1566 (1986); Tsubota et al., J. Exp. Med. 169:1421-1434 (1989); Walker and Levy, Immunology 66:628-630 (1989); Mackewicz et al., J. Clin. Invest. 87:1462-1466, (1991); van Kuyk et al., J. Immunol. 153:4826-4833 (1994)).  
5 Such soluble factors include the chemokines RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$  (Cocchi et al., Science 270:1811-1815 (1995)).

The present disclosure provides the first demonstration of protection against mucosal viral challenge mediated by CTL, which must be present in the local mucosa.  
10 Also provided are methods and compositions for enhancing the induction of such local mucosal CTL by a peptide vaccine given together with recombinant IL-12 at the mucosal site. These methods and compositions for stimulating CTL immunity at local sites of mucosal exposure represent important tools for  
15 vaccine development to prevent HIV infection or disease in humans. Because the gastrointestinal tract appears to be a major site of early SIV and HIV replication, among other pathogens, and because this and other mucosal sites are frequent sites of entry for these pathogens, it is  
20 particularly critical to achieve protection at mucosal sites. The present disclosure satisfies these objects and provides other advantages as set forth above.

Although the invention has been described with  
25 reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.



WHAT IS CLAIMED IS:

1. A method for inducing a protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a mucosal tissue of the subject with a composition comprising a purified soluble antigen.

2. The method of claim 1, wherein the soluble antigen is an antigenic peptide.

3. The method of claim 1, wherein said composition further comprises an adjuvant.

4. The method of claim 3, wherein the adjuvant is selected from cholera toxin (CT), mutant cholera toxin (MCT), or mutant- E. coli heat labile enterotoxin (MLT).

5. The method of claim 1, further comprising administering a purified cytokine to the subject.

6. The method of claim 1, wherein the cytokine is contacted with a mucosal surface of the subject.

7. The method of claim 5, wherein the purified cytokine is selected from granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor  $\alpha$  (TNF $\alpha$ ).

8. The method of claim 1, further comprising administering purified interferon- $\gamma$  to the subject.

9. The method of claim 8, wherein the purified interferon- $\gamma$  is contacted with a mucosal surface of the subject.

10. The method of claim 5, further comprising administering purified interferon- $\gamma$  to the subject.

11. The method of claim 10, wherein the purified interferon- $\gamma$  is contacted with a mucosal surface of the subject.

5 12. The method of claim 1, wherein said composition further comprises a purified cytokine selected from granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor.

10 13. The method of claim 1, wherein said composition further comprises purified interferon- $\gamma$ .

15 14. The method of claim 12, wherein said composition further comprises purified interferon- $\gamma$ .

15 15. The method of claim 1, wherein the antigen is a peptide derived from a pathogenic virus.

20 16. The method of claim 15, wherein the pathogenic virus is *HIV-1*.

25 17. The method of claim 15, wherein the pathogenic virus is influenza virus.

25 18. The method of claim 15, wherein the pathogenic virus is rotavirus.

30 19. The method of claim 1, wherein the antigen is a peptide derived from a pathogenic bacterium or protozoan.

20. The method of claim 1, wherein the antigen is a tumor-associated peptide.

35 21. The method of claim 1, wherein the antigen is a peptide comprising an *HIV-1* cluster peptide vaccine construct (CLUVAC) selected from the group consisting of:  
EQMHEDIISLWDQSLKPCVKRIQRGPGRAFVTIGK (SEQ ID NO:1),

KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTIGK (SEQ ID NO:2),  
RDNWRSELYKYKVVKIEPLGVAPTRIQRGPGRAFVTIGK (SEQ ID NO:3),  
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK (SEQ ID  
NO:4), DRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK (SEQ ID  
5 NO:5), DRVIEVVQGAYRAIRRIQRGPGRAFVTIGK (SEQ ID NO:6),  
AQGAYRAIRHIPRRIRRIQRGPGRAFVTIGK (SEQ ID NO:7),  
EQMHEDIISLWDQSLKPCVKRIHIGPGRAFYTCKN (SEQ ID NO:8),  
KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTCKN (SEQ ID NO:9),  
RDNWRSELYKYKVVKIEPLGVAPTRIHIGPGRAFYTCKN (SEQ ID NO:10),  
10 AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTCKN (SEQ ID  
NO:11), DRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTCKN (SEQ ID  
NO:12), DRVIEVVQGAYRAIRRIHIGPGRAFYTCKN (SEQ ID NO:13) and  
AQGAYRAIRHIPRRIRRIHIGPGRAFYTCKN (SEQ ID NO:14).

15 22. The method of claim 21, wherein the HIV-1 CLUVAC  
is HIV-1 CLUVAC PCLUS3-18IIIB (SEQ ID NO:2).

23. The method of claim 21, wherein the HIV-1 CLUVAC  
is HIV-1 CLUVAC PCLUS3-18MN (SEQ ID NO:9).

20 24. The method of claim 21, wherein the HIV-1 CLUVAC  
is HIV-1 CLUVAC PCLUS 6.1-18MN (SEQ ID NO:12).

25 25. A method for inducing a protective mucosal CTL  
response in a subject, comprising contacting a mucosal tissue  
of the subject with a composition comprising a soluble  
antigen, wherein said composition does not comprise an  
adjuvant.

30 26. The method of claim 25, further comprising  
administering a purified cytokine to the subject.

27. The method of claim 25, wherein the cytokine is  
contacted with a mucosal surface of the subject.

35 28. The method of claim 27, wherein the purified  
cytokine is selected from granulocyte-macrophage colony-  
stimulating factor (GM-CSF), interleukin-2 (IL-2),

interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor  $\alpha$  (TNF $\alpha$ ).

29. The method of claim 25, further comprising  
5 administering purified interferon- $\gamma$  to the subject.

30. The method of claim 29, wherein the purified  
interferon- $\gamma$  is contacted with a mucosal surface of the  
subject.

10

31. The method of claim 26, further comprising  
administering purified interferon- $\gamma$  to the subject.

32. The method of claim 31, wherein the purified  
15 interferon- $\gamma$  is contacted with a mucosal surface of the  
subject.

33. The method of claim 25, wherein said composition  
further comprises a purified cytokine selected from  
20 granulocyte-macrophage colony-stimulating factor (GM-CSF),  
interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12  
(IL-12) or tumor necrosis factor.

34. The method of claim 25, wherein said composition  
25 further comprises purified interferon- $\gamma$ .

35. The method of claim 33, wherein said composition  
further comprises purified interferon- $\gamma$ .

36. The method of claim 25, wherein the antigen is a  
30 peptide derived from a pathogenic virus.

37. The method of claim 36, wherein the pathogenic  
virus is HIV-1.

35

38. The method of claim 36, wherein the pathogenic  
virus is influenza virus.

39. The method of claim 36, wherein the pathogenic virus is rotavirus.

5 40. The method of claim 25, wherein the antigen is a peptide derived from a pathogenic bacterium or protozoan.

41. The method of claim 25, wherein the antigen is a tumor-associated peptide.

10 42. The method of claim 25, wherein the antigen is a peptide comprising an *HIV-1* cluster peptide vaccine construct (CLUVAC) selected from the group consisting of:

EQMHEDIISLWDQSLKPCVKRIQRGPGRAFVTIGK (SEQ ID NO:1),  
KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTIGK (SEQ ID NO:2),  
15 RDNWRSELYKYKVVKIEPLGVAPTRIQRGPGRAFVTIGK (SEQ ID NO:3),  
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK (SEQ ID NO:4),  
DRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK (SEQ ID NO:5),  
DRVIEVVQGAYRAIRRIQRGPGRAFVTIGK (SEQ ID NO:6),  
AQGAYRAIRHIPRRIRRIQRGPGRAFVTIGK (SEQ ID NO:7),  
20 EQMHEDIISLWDQSLKPCVKRIHIGPGRAFYTTKN (SEQ ID NO:8),  
KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9),  
RDNWRSELYKYKVVKIEPLGVAPTRIHIGPGRAFYTTKN (SEQ ID NO:10),  
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN (SEQ ID NO:11),  
DRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN (SEQ ID NO:12),  
25 NO:12), —DRVIEVVQGAYRAIRRIHIGPGRAFYTTKN (SEQ ID NO:13) and  
AQGAYRAIRHIPRRIRRIHIGPGRAFYTTKN (SEQ ID NO:14).

30 43. The method of claim 42, wherein the *HIV-1* CLUVAC is *HIV-1* CLUVAC PCLUS3-18IIIB (SEQ ID NO:2).

44. The method of claim 42, wherein the *HIV-1* CLUVAC is *HIV-1* CLUVAC PCLUS3-18MN (SEQ ID NO:9).

35 45. The method of claim 42, wherein the *HIV-1* CLUVAC is *HIV-1* CLUVAC PCLUS 6.1-18MN (SEQ ID NO:12).

46. An immunogenic composition for inducing a protective mucosal CTL response in a subject and adapted for

intrarectal administration comprising a purified soluble antigen formulated for intrarectal delivery to the rectum, colon, sigmoid colon, or distal colon.

5           47. The immunogenic composition of claim 46, which comprises a rectal enema, foam, suppository, or topical gel.

          48. The immunogenic composition of claim 46, further comprising a base, carrier, or absorption-promoting agent  
10 adapted for intrarectal delivery.

          49. The immunogenic composition of claim 48, which includes a rectal emulsion or gel preparation.

15           50. The immunogenic composition of claim 48, wherein the soluble antigen is admixed with a homogenous gel carrier.

          51. The immunogenic composition of claim 48, wherein the homogenous gel carrier is a polyoxyethylene gel.  
20

          52. The immunogenic composition of claim 48, wherein the soluble antigen is admixed with a rectally-compatible foam.

25           53. The immunogenic composition of claim 48, wherein the soluble antigen is formulated in a suppository.

          54. The immunogenic composition of claim 53, wherein the suppository is comprised of a base selected from a  
30 polyethyleneglycol, witepsol H15, witepsol W35, witepsol E85, propyleneglycol dicaprylate (Sefsol 228), Miglyol 810, hydroxypropylcellulose-H (HPC), or carbopol-934P (CP).

          55. The immunogenic composition of claim 53,  
35 comprising at least two base materials.

56. The immunogenic composition of claim 46, including a stabilizing agent to minimize intrarectal degradation of the soluble antigen.

5 57. The immunogenic composition of claim 46, including an absorption-promoting agent.

58. The immunogenic composition of claim 57, wherein the absorption-promoting agent is selected from a surfactant, mixed micelle, enamines, nitric oxide donor, sodium salicylate, glycerol ester of acetoacetic acid, clyclodextrin or beta-cyclodextrin derivative, or medium-chain fatty acid.

59. The immunogenic composition of claim 46, further comprising an adjuvant.

60. The immunogenic composition of claim 59, wherein the adjuvant is selected from cholera toxin (CT), mutant cholera toxin (MCT), mutant- E. coli heat labile enterotoxin, or pertussis toxin.

61. The immunogenic composition of claim 59, wherein the adjuvant is conjugated to a mucosal tissue or T cell binding agent.

62. The immunogenic composition of claim 61, wherein the mucosal tissue or T cell binding agent is selected from protein A, an antibody that binds a mucosal tissue- or T-cell-specific protein, or a ligand or peptide that binds a mucosal tissue- or T-cell-specific protein.

63. The immunogenic composition of claim 59, wherein the adjuvant comprises a recombinant cholera toxin (CT) having a B chain of CT substituted by protein A conjugated to a CT A chain to eliminate toxicity and enhance mucosal tissue binding mediated by protein A.

64. The immunogenic composition of claim 59, wherein the adjuvant is conjugated to a protein or peptide that binds specifically to T cells.

5           65. The immunogenic composition of claim 64, wherein the protein or peptide binds to CD4 or CD8.

10           66. The immunogenic composition of claim 66, wherein the protein or peptide is an HIV V3 loop or T cell-binding peptide fragment thereof.

67. The immunogenic composition of claim 59, further comprising purified IL-12.


15           68. The immunogenic composition of claim 59, further comprising purified interferon- $\gamma$ .

20           69. The immunogenic composition of claim 68, further comprising purified IL-12.



1/17

FIG. 1



4 Rec'd PCT/PTO 09 MAR 00

2/17

FIG. 3





FIG. 2



514 Rec'd PCT/PTO 09 MAR 2000

FIG. 4





FIG. 5



514 Rec'd PCT/PTC 09 MAR 2000

4/17

FIG. 6A





FIG. 6B



514 Rec'd PCT/PTO 0 9 MAR 2000



5/17

FIG. 7A





FIG. 7B



514 Rec'd PCT/PTO 09 MAR 2000

6/17

FIG. 8A





FIG. 8B




314 Rec'd PCV/PTO 09 MAR 2000

7

7/17


FIG. 9A



5 ec'd PCT/PTO 09 MAR 2008

8/17


FIG. 9B



4 Rec'd PCUPTO 09 MAR 2000




9/17



514 Rec'd PCT/PTO 0 9 MAR 2000

17

10/17



514 Rec'd PCT/PTO 09 MAR 2000

11/17

FIG. 11





FIG. 12



514 Rec'd PCT/PTO 09 MAR 2006

3577

12/17

FIG. 13





FIG. 14A



514 Rec'd PCT/PTO 0 9 MAR 2000





13/17

FIG. 14B






FIG. 16



514 Rec'd PCT/PTO 09 M 2000

14/17


FIG. 15A



514 Rec'd PCT/PTO 0 9 MAR 2000


15/17

FIG. 15B



514 Rec'd PCT/PTO 09 2000


FIG. 17A



514 Rec'd PCT/PTO 09 M 2000



FIG. 17B



514 Rec'd PCT/PTO 0 9 2000

77

## SEQUENCE LISTING

<110> Berzofsky, Jay A.  
 Belyakov, Igor M.  
 Derby, Michael A.  
 Kelsall, Brian L.  
 Strober, Warren

THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as

<120> MUCOSAL CYTOTOXIC T LYMPHOCYTE RESPONSES

<130> 368200PCSEQ

<140> PCT/US98/

<141> 1998-09-11

<150> 60/058,523

<151> 1997-09-11

<150> 60/074,894

<151> 1998-02-17

<160> 20

<170> PatentIn Ver. 2.0

<210> 1

<211> 35

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 1

Glu	Gln	Met	His	Glu	Asp	Ile	Ile	Ser	Leu	Trp	Asp	Gln	Ser	Leu	Lys
1				5				10				15			

Pro	Cys	Val	Lys	Arg	Ile	Gln	Arg	Gly	Pro	Gly	Arg	Ala	Phe	Val	Thr
			20					25					30		

Ile	Gly	Lys
		35

<210> 2

<211> 39

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 2

1000

1000

1000

Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala  
1 5 10 15

Pro Pro Ile Ser Gly Gln Ile Arg Arg Ile Gln Arg Gly Pro Gly Arg  
20 25 30

Ala Phe Val Thr Ile Gly Lys  
35

<210> 3

<211> 39

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 3

Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile  
1 5 10 15

Glu Pro Leu Gly Val Ala Pro Thr Arg Ile Gln Arg Gly Pro Gly Arg  
20 25 30

Ala Phe Val Thr Ile Gly Lys  
35

<210> 4

<211> 48

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 4

Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val Val Gln Gly Ala  
1 5 10 15

Tyr Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu  
20 25 30

Arg Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys  
35 40 45

<210> 5

<211> 42

<212> PRT



<213> Human immunodeficiency virus type 1

<400> 5

Asp Arg Val Ile Glu Val Val Gln Gly Ala Tyr Arg Ala Ile Arg His  
1 5 10 15

Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu Arg Arg Ile Gln Arg Gly  
20 25 30

Pro Gly Arg Ala Phe Val Thr Ile Gly Lys  
35 40

<210> 6

<211> 30

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 6

Asp Arg Val Ile Glu Val Val Gln Gly Ala Tyr Arg Ala Ile Arg Arg  
1 5 10 15

Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys  
20 25 30

<210> 7

<211> 32

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 7

Ala Gln Gly Ala Tyr Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg  
1 5 10 15

Arg Ile Gln Arg Gly Pro Gly Pro Arg Ala Phe Val Thr Ile Gly Lys  
20 25 30

<210> 8

<211> 35

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 8





Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Gln Ser Leu Lys  
1 5 10 15

Pro Cys Val Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr  
20 25 30

Thr Lys Asn  
35

<210> 9

<211> 39

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 9

Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala  
1 5 10 15

Pro Pro Ile Ser Gly Gln Ile Arg Arg Ile His Ile Gly Pro Gly Arg  
20 25 30

Ala Phe Tyr Thr Thr Lys Asn  
35

<210> 10

<211> 39

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 10

Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile  
1 5 10 15

Glu Pro Leu Gly Val Ala Pro Thr Arg Ile His Ile Gly Pro Gly Arg  
20 25 30

Ala Phe Tyr Thr Thr Lys Asn  
35

<210> 11

<211> 48

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 11



Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val Val Gln Gly Ala  
1 5 10 15

Tyr Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu  
20 25 30

Arg Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn  
35 40 45

<210> 12

<211> 42

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 12

Asp Arg Val Ile Glu Val Val Gln Gly Ala Tyr Arg Ala Ile Arg His  
1 5 10 15

Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu Arg Arg Ile His Ile Gly  
20 25 30

Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn  
35 40

<210> 13

<211> 30

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 13

Asp Arg Val Ile Glu Val Val Gln Gly Ala Tyr Arg Ala Ile Arg Arg  
1 5 10 15

Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn  
20 25 30

<210> 14

<211> 31

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 14



Ala Gln Gly Ala Tyr Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg  
1 5 10 15

Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn  
20 25 30

<210> 15

<211> 15

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 15

Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys  
1 5 10 15

<210> 16

<211> 10

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 16

Arg Gly Pro Gly Arg Ala Phe Val Thr Ile  
1 5 10

<210> 17

<211> 20

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 17

Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Gln Ser Leu Lys  
1 — 5 10 15

Pro Cys Val Lys  
20

<210> 18

<211> 24

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 18

Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala  
1 5 10 15



Pro Pro Ile Ser Gly Gln Ile Arg  
20

<210> 19

<211> 24

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 19

Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile  
1 5 10 15

Glu Pro Leu Gly Val Ala Pro Thr  
20

<210> 20

<211> 33

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 20

Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val Val Gln Gly Ala  
1 5 10 15

Tyr Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu  
20 25 30

Arg

